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ABSTRACT
Variations in DNA repair genes have been reported as key factors in gastric 
cancer (GC) susceptibility but results among studies are inconsistent. We aimed to 
assess the relevance of DNA repair gene polymorphisms and environmental factors 
to GC risk and phenotype in a Caucasian population in Spain. Genomic DNA from 603 
patients with primary GC and 603 healthy controls was typed for 123 single nucleotide 
polymorphisms in DNA repair genes using the Illumina platform. Helicobacter pylori 




Gastric cancer (GC) represents the fifth most 
common neoplasia and the third leading cause of cancer–
related death worldwide [1]. Despite continuous advances 
in diagnosis and treatment, most patients with GC present 
with late–stage disease and poor prognosis. Therefore, it 
is not surprising that detection of potential risk factors 
is regarded as the most effective option to prevent and 
reduce the incidence of GC.
GC is a heterogeneous disease that shows distinct 
clinical, epidemiological, and molecular features 
among tumors arising from the proximal (cardia) or 
distal (non–cardia) stomach, and among intestinal and 
diffuse histological subtypes [2, 3]. These differences in 
phenotype seem to be determined by complex interactions 
between environmental and host genetic factors. Among 
them, Helicobacter pylori (H. pylori) infection has been 
identified as the single most common cause of GC [4]. 
This organism, which colonizes over half of the world’s 
population, first induces a chronic superficial gastritis in 
virtually all infected people, initiating a process that in 
certain individuals may lead to GC [5]. Several studies 
have found that bacterial virulence determinants, such 
as the presence of the CagA pathogenicity island, 
are associated with a higher risk of GC development 
[6, 7]. However, why only a minority (< 1%) of infected 
individuals develops gastric malignancy remains a matter 
of speculation, suggesting that factors other than bacterial 
infection alone are involved in the carcinogenesis process.
Additional host genetic factors are also likely to 
contribute in gastric carcinogenesis. In this respect, genetic 
susceptibility may be critical in several relevant processes 
such as mucosal protection, immune response, carcinogen 
detoxification, antioxidant protection, cell proliferation, 
and DNA repair [8]. Concerning the latter, a complex 
system involving multiple enzymes and pathways plays a 
crucial role in maintaining genome homeostasis in the face 
of exogenous and endogenous agents and general DNA 
replication errors. In this context, five major DNA repair 
pathways have been described: i) base excision repair 
(BER) fixes simple base modifications (oxidized/reduced 
bases) and DNA single-strand breaks caused by ionizing 
radiation, alkylating agents, and oxidative stress [9]; ii) 
nucleotide excision repair (NER) repairs the damage 
caused by bulky adducts produced by ultraviolet light and 
a wide array of chemical agents [10]; iii) mismatch repair 
(MMR) removes base–base mismatches, small loops, 
and insertion/deletion mispairs occurring during DNA 
replication and recombination [11]; iv) double–strand 
break repair (DSBR) evolves two main mechanisms, non–
homologous end joining and homologous recombination 
repair, whichrepair the most severe type of DNA 
damage [12] and v) direct reversion repair (DR) corrects 
methylated bases, namely O6-methylguanine (O6MeG), 
induced by alkylating agents [13]. 
DNA repair genes harbor functional polymorphic 
regions that have been reported to influence the host 
capacity to repair damaged DNA. Therefore, it is plausible 
that individuals carrying deficient DNA repair alleles 
will be at greater risk of presenting mutations that can 
alter genome integrity and stability leading to cancer 
development. Common single nucleotide polymorphisms 
(SNPs) in DNA repair genes have been identified as 
potential risk factors for a wide array of cancers, including 
lung [14], ovarian [15], prostate [16], and breast cancer 
[17]. However, the data are not conclusive concerning 
the relationship between DNA repair variants and GC; 
whereas some studies report a link with GC risk [18, 19] 
or anatomopathological subtypes [20, 21], other studies 
have failed to confirm any associations [22, 23]. 
Trying to address this issue, we sought to 
evaluate the influence of 123 selected DNA repair gene 
polymorphisms and environmental factors (H. pylori 
infection and smoking habits) to GC risk and phenotype 
in a Caucasian population in Spain. Because GC shows 
marked heterogeneity in histology and anatomic 
involvement, we aimed also to analyze the role of both 
environmental and host genetic factors with regard to the 
site and histological type of the tumor. 
RESULTS
Clinical and demographic characteristics of GC 
patients and healthy controls
The clinical and demographic characteristics of 
GC patients and healthy controls (HCs) are shown in 
1.55–2.54), tobacco smoking (OR: 1.77; 95% CI: 1.22–2.57), and family history of 
GC (OR: 2.87; 95% CI: 1.85–4.45) were identified as independent risk factors for GC. 
By contrast, the TP53 rs9894946A (OR: 0.73; 95% CI: 0.56–0.96), TP53 rs1042522C 
(OR: 0.76; 95% CI: 0.56–0.96), and BRIP1 rs4986764T (OR: 0.55; 95% CI: 0.38–0.78) 
variants were associated with lower GC risk. Significant associations with specific 
anatomopathological GC subtypes were also observed, most notably in the ERCC4 
gene with the rs1799801C, rs2238463G, and rs3136038T variants being inversely 
associated with cardia GC risk. Moreover, the XRCC3 rs861528 allele A was significantly 
increased in the patient subgroup with diffuse GC (OR: 1.75; 95% CI: 1.30–2.37). Our 
data show that specific TP53, BRIP1, ERCC4, and XRCC3 polymorphisms are relevant 
in susceptibility to GC risk and specific subtypes in Caucasians.
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Table 1. Of the 603 patients with GC, 117 (19.4%) were 
classified as cardia and 486 (80.6%) as non–cardia GC 
cases. According to Lauren’s classification [3], non–cardia 
gastric adenocarcinomas were of intestinal histotype in 
250 patients (51.4%), diffuse histotype in 178 patients 
(36.6%), and mixed or undetermined type in 58 patients 
(11.9%). Among the evaluated features, infection 
with H. pylori and CagA+ strains was significantly 
associated with a higher risk of GC (H. pylori, odds ratio 
(OR): 1.38; 95% confidence interval (CI): 1.09–1.76; 
P = 0.008; CagA+ strains, OR: 1.95; 95% CI: 1.54–2.46; 
P < 0.0001). However, no differences in the prevalence 
of VacA+ strains were observed between GC patients 
and controls (40.1% vs. 39.3%). When considering the 
anatomic location of the tumor, infection with CagA+ 
strains was specifically associated with a higher risk of 
developing non–cardia GC (62.6% vs. 41.3%; OR: 2.32; 
95% CI: 1.80–2.98; P < 0.0001) (Supplementary Table 1). 
Of interest, no association between H. pylori infection and 
cardia GC was found. Among non–cardia GC patients, H. 
pylori infection with CagA+ strains was significantly more 
frequent in both diffuse and intestinal tumor subtypes 
compared with controls (OR: 3.02; 95% CI: 2.08–4.37; 
P < 0.0001 vs. HC; and OR: 2.25; 95% CI: 1.65–3.07; 
P < 0.0001 vs. HC, respectively).
In addition to H. pylori infection, active smoking 
(OR: 1.53; 95% CI: 1.12–2.09) and family history of GC 
(OR: 3.02; 95%: 1.99–4.60) were also found to be risk 
factors for the development of GC (Table 1). Stratified 
analysis by tumor location showed that smoking habit 
was strongly associated with cardia GC (OR: 2.93; 95% 
CI: 1.68–5.11; P = 0.0002) whereas a positive family 
history of GC was specifically associated with a higher 
risk of non–cardia GC (OR: 3.29; 95% CI: 2.14–5.06; 
P < 0.0001), (Supplementary Table 1). 
Genotyping
Single marker analysis
Of the 123 SNPs initially evaluated in our study, 
108 SNPs were successfully genotyped in 1206 subjects 
(603 GC patients and 603 HCs) and available for analysis. 
Supplementary Table 2 summarizes the genotype 
distribution of each polymorphism in GC patients and 
controls according to the location and histological type 
of the tumor. Genotype frequencies did not deviate 
significantly from those expected under Hardy–Weinberg 
equilibrium in the control group. Moreover, no evidence 
of genetic heterogeneity among study participants, either 
patients or controls, was observed (data not shown). 
Fourteen SNPs (TP53 rs1042522, RAD52 rs11226, 
ERCC5 rs17655, POLG rs176641, BRCA2 rs1801406, 
LIG3 rs2074522, XPC rs2228000, ERCC4 rs2238463, 
MGMT rs2308321, MSH3 rs26779, ERCC4 rs3136038, 
BRIP1 rs4986764, XRCC3 rs861528, and TP53 
rs9894946) revealed significant associations with GC 
risk (P < 0.05) in at least one of the four genetic models 
evaluated in the analysis (Supplementary Table 3). 
However, after false discovery rate (FDR) multiple test 
correction, only four SNPs in the TP53 (rs1042522G>C, 
rs9894946G>A), LIG3 (rs2074522G>A), and BRIP1 
(rs4986764C>T) genes retained significance (Table 2). 
Thus, the TP53 rs1042522C and TP53 rs9894946A 
variants were inversely associated with GC risk (dominant 
models, OR: 0.67; 95% CI: 0.53–0.85; and OR: 0.69; 95% 
CI: 0.53–0.90, respectively). The BRIP1 rs4986764T 
variant also showed a protective effect (recessive model, 
OR: 0.59; 95% CI: 0.42–0.83). By contrast, the rare allele 
A of LIG3 rs2074522 was associated with a higher risk of 
developing the disease (recessive model, OR: 0.59; 95% 
CI: 1.58–31.5).
None of the 108 DNA repair gene polymorphisms 
analyzed in our study were significantly associated with 
prevalence of infection with H. pylori or CagA/VacA 
strains (Supplementary Table 4). Of note, when subgroup 
analysis by H. pylori infection status was performed, the 
previously reported risk associations of TP53 rs1042522, 
TP53 rs9894946G, LIG3 rs2074522, and BRIP1 
rs4986764 with GC were observed only in the group 
of H. pylori–infected individuals (Table 2). However, 
after FDR corrections, these associations did not remain 
significant with the exception of TP53 rs1042522 (P72R). 
Tests for interaction under a multiplicative model showed 
no statistically significant interactions between TP53 
rs1042522 genotypes and H. pylori infection (P-interaction= 
0.081, dominant model). 
On the other hand, stratified analysis by tumor 
location (cardia/distal) and histological type of GC 
(intestinal/diffuse) showed significant associations with 
specific GC subtypes (Supplementary Tables 5 and 6). 
Table 3 summarizes those SNPs significantly associated 
with GC subtypes after applying the FDR correction 
test. Of interest, three SNPs (rs1799801, rs2238463, 
and rs3136038) located in the NER gene ERCC4 were 
inversely associated with cardia GC risk. The ERCC4 
rs2238463 and rs3136038 loci were in strong linkage 
disequilibrium (LD) in our data set (D’ = 1, r2 = 0.92) 
with lower values for the rs1799801/rs2238463 (D’ = 
0.98, r2 = 0.70), and rs1799801/rs3136038 (D’ = 0.93, r2 = 
0.69) loci. In addition, carriers of the XRCC3 rs861528A 
and POLG rs176641C variants were significantly 
increased in the subgroup of patients with non–cardia 
GC compared to controls (dominant models, OR: 1.45; 
95% CI: 1.11–1.88; and OR: 1.40, 95% CI: 1.09–1.81, 
respectively). By contrast, the XPC rs2228000T variant 
was associated with a lower risk of non–cardia GC 
(dominant model, OR: 0.70; 95% CI: 0.55–0.90). When 
considering the histological type of tumor, the most 
remarkable association was observed in the DSBR gene 
XRCC3, with the A allele of rs861528 being associated 
with a higher risk of diffuse GC (dominant model, OR: 
2.11; 95% CI: 1.43–3.12) (Table 3.).
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Finally, no significant differences in genotype 
distribution and allele frequencies between GC patients 
and controls were found when subjects were stratified 
according to other evaluated features such as age, gender, 
smoking habit, and family history of GC (Supplementary 
Tables 7–10).
Haplotype analysis
The comparisons of common haplotype frequencies 
(> 0.05) in each gene block between GC patients and 
controls are presented in Supplementary Table 11. 
Haplotype analysis revealed significant differences 
in four blocks covering the BRIP1, ERCC4, ERCC5, 
and TP53 genes (Table 4, Figure 1). The most robust 
association was observed in the TP53 block. Thus, the 
haplotype rs1042522C, rs1614984C, and rs9894946A, 
at a frequency of 10% in our population, was inversely 
associated with GC risk (12% in HC vs. 8% in GC; 
OR: 0.68; 95% CI: 0.51–0.91). This haplotype contains 
the rs1042522C and rs9894946A alleles previously 
reported in the single SNP analysis as protective factors 
Table 1: Demographic and clinical characteristics of healthy controls and gastric cancer patients
Healthy Controls n = 603 GC patients n = 603 ORs (95% CI) P Value
Age yrs ± SD (range) 70.17 ± 12.32 70.32 ± 12.27 0.97
(30–96) (29–96)
Gender 413 M (68.5%) 413 M (68.5%)
190 F (31.5%) 190 F (31.5%) 1 (0.78–1.27) 1.04
aCigarette smoking
       Never 311/585 (53.2%) 291/582 (50%) Reference
       Former 184/585 (31.4%) 162/582 (27.8 %) 0.94 (0.72–1.23) 0.68
       Current smoker 90/585 (15.4%) 129/582 (22.2%) 1.53 (1.12–2.09) 0.009
bH.  pylori + 364 (60.4%) 377/556 (67.8%) 1.38 (1.09–1.76) 0.008
       CagA+ 253 (41.9%) 325/556 (58.4%) 1.95 (1.54–2.46) < 0.0001
       VacA+ 237 (39.3%) 223/556 (40.1%) 1.03 (0.82–1.31) 0.81
cFamily history of GC 33/539 (6.1%) 88/534 (16.5%) 3.02 (1.99–4.60) < 0.0001
Neoplasia location
       Cardia 117 (19.4%)
       Non–cardia 486 (80.6%)
Lauren’s classification
       Intestinal 250 (51.4%)
       Diffuse 178 (36.6%)
       Mixed or undetermined 58 (11.9%)
dTNM stage
       Stage I 80 (13.3%)
       Stage II 79 (13.1%)
       Stage III 131 (21.7%)
       Stage IV 264 (43.8%)
Could not be assessed 49 (8.1%)
Surgical treatment 410 (68%)
Chemotherapy 225 (37.3%)
Radiotherapy 105 (17.4%)
GC, gastric cancer; n, number of individuals; OR, odds ratio; CI, confidence interval; SD, standard deviation; M, male; F, female. 
aInformation was available for 585 HC and 582 GC patients. 
bHelicobacter pylori infection and CagA/VacA antibody data obtained by western blot analysis in serum samples. Information 
was available for 603 HC and 556 GC patients.
cInformation was available for 539 HC and 534 GC patients.
dClinical tumor stages according to the International Union Against Cancer (UICC) criteria. In 49 GC patients tumor stage 
could not be assessed.
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for the development of GC. In the same way, the BRIP1 
(rs2048718T, rs4968451C, rs4986764T) and ERCC4 
(rs1799801T, rs1800067G, rs2238463G, rs3136038T) 
haplotypes carry the risk alleles identified in the single 
SNP–based analysis, associated with overall GC risk 
and cardial subtype, respectively. Stratified haplotype 
analysis by tumor location and GC histological type did 
not provide additional information beyond individual SNP 
results (data not shown).
Multivariate analysis
In summary, of the environmental and genetic 
factors evaluated in this study, logistic regression analysis 
Figure 1: Linkage disequilibrium (LD) maps covering the BRIP1, ERCC4, and TP53 genes. LD maps based on pairwise 
r2 values for SNPs investigated in the (A) BRIP1 gene, (B) ERCC4 gene, and (C) TP53 gene. Gene annotations obtained from the UCSC 
genome browser. Only LD maps of haplotypes in DNA repair genes significantly associated with gastric cancer risk (P < 0.05) are shown 
in the figure.
Table 2: Association of DNA repair gene polymorphisms with GC risk
HC Genotype GC Genotype Dominant model Recessive model Log-Additive model




TP53  rs1042522 G/C Overall n 314 247 40 372 192 39 0.67 (0.53–0.85) 0.001 0.012 1.05 (0.66–1.67) 0.832 0.896 0.78 (0.65–0.94) 0.009 0.068
H. pylori + 180 159 23 241 115 21 0.55 (0.41–0.74) 0.0001 0.002 0.85 (0.46–1.58) 0.619 0.734 0.65 (0.51–0.83) 0.001 0.013
H. pylori – 134 88 17 103 59 17 0.95 (0.64–1.41) 0.803 0.902 1.35 (0.66–2.74) 0.413 0.912 1.02 (0.76–1.39) 0.875 0.983
TP53  rs9894946 G/A Overall n 409 165 18 452 138 6 0.69 (0.53–0.90) 0.006 0.013 0.23 (0.08–0.68) 0.002 0.014 0.66 (0.52–0.85) 0.001 0.017
H. pylori + 249 98 11 288 82 3 0.65 (0.46–0.91) 0.019 0.095 0.27 (0.07–0.97) 0.021 0.143 0.64 (0.47–0.87) 0.004 0.053
H. pylori – 160 67 7 132 44 1 0.73 (0.47–1.14) 0.168 0.832 0.19 (0.02–1.57) 0.065 0.674 0.70 (0.47–1.05) 0.085 0.659
LIG3  rs2074522 G/A Overall n 509 89 2 496 94 13 1.22 (0.89–1.67) 0.217 0.268 7.05 (1.58–31.5) 0.001 0.014 1.32 (0.99–1.75) 0.055 0.080
H. pylori + 306 54 2 309 59 9 1.23 (0.83–1.81) 0.302 0.393 4.3 (0.92–20.28) 0.035 0.143 1.30 (0.92–1.85) 0.135 0.201
H. pylori – 203 35 – 148 27 4 1.16 (0.68–1.97) 0.591 0.902 NA NA 1.33 (0.80–2.11) 0.296 0.659
BRIP   rs4986764 C/T Overall n 224 270 107 232 297 69 0.94 (0.74–1.20) 0.633 0.724 0.59 (0.42–0.83) 0.002 0.015 0.85 (0.72–1.00) 0.055 0.075
H. pylori + 134 166 64 145 188 42 0.93 (0.69–1.26) 0.657 0.603 0.58 (0.38–0.89) 0.011 0.143 0.84 (0.68–1.04) 0.106 0.180
H. pylori – 90 104 43 68 89 21 0.99 (0.66–1.48) 0.866 0.908 0.62 (0.35–1.09) 0.089 0.686 0.87 (0.66–1.16) 0.451 0.836
Stratified analysis by H. pylori infection status.
HC, healthy control; GC, gastric cancer; n, number of individuals.
A/a, major/minor alleles; OR, odds ratio; CI, confidence interval; NA, not applied.
aP-values, ORs, and 95% CIs adjusted by gender, age, smoking habit, and family history of GC.
bQFDR-values obtained after applying the False Discovery Rate (FDR) test. 
P-values < 0.05 are highlighted in bold.
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identified H. pylori infection with CagA strains (OR: 1.99; 
95% CI: 1.55–2.54), smoking habit (OR: 1.77; 95% CI: 
1.22–2.57), and positive family history of GC (OR: 2.87; 
95% CI: 1.85–4.45) as independent risk factors for the 
development of GC. Concerning genetic factors, the LIG3 
rs2074522 polymorphism was associated with a higher 
risk of GC (OR: 5.67; 95% CI: 1.24–25.95, recessive 
model) whereas the TP53 rs9894946 (OR:0.73; 95% CI: 
0.56–0.96, log-additive model), TP53 rs1042522 (OR: 
0.76; 95% CI: 0.56–0.96, dominant model), and BRIP1 
rs4986764 (OR: 0.55; 95% CI: 0.38–0.78, recessive 
model) variants were associated with a lower risk of 
developing the disease (Table 5).
DISCUSSION
Over the last few years, numerous studies 
concerning the association between DNA repair gene 
polymorphisms and GC risk have been conducted in 
different geographic areas and ethnic groups. However, 
most studies have yielded inconsistent and discrepant 
results [18, 19, 22, 23]. To assess the relevance of DNA 
repair gene polymorphisms to GC susceptibility and 
phenotype, we analyzed a total of 123 SNPs located in 52 
genes involved in different DNA repair pathways. 
In our population, four SNPs located in the TP53 
(rs1042522G>C, rs9894946G>A), LIG3 (rs2074522G>A), 
and BRIP1 (rs4986764C>T) genes were significantly 
associated with GC susceptibility after FDR multiple 
test correction. Thus, allele A of LIG3 rs2074522 was 
associated with a higher risk of GC whereas the TP53 
rs9894946A, TP53 rs1042522C, and BRIP1 rs4986764T 
variants were associated with a lower risk of developing 
the disease. Interestingly, these four variants are located 
in the long (LIG3 q11.2–q12, BRIP1 q22.2) and short 
arms (TP53 p.13.1) of chromosome 17, suggesting that 
this region of the genome represents a promising target for 
more extensive investigations in the field of GC research.
TP53 (tumor protein p53) is a tumor suppressor 
gene that encodes a potent nuclear transcription factor 
with a fundamental role in the maintenance of genomic 
stability. When activated in response to cellular stress, the 
p53 protein induces cell cycle arrest and apoptosis, inhibits 
cell growth, and interacts with proteins involved in DNA 
repair [24]. High frequencies of somatic mutations in the 
TP53 gene and/or overexpression of p53 protein have been 
reported in many types of human cancers, including GC 
[25]. Although TP53 is a highly polymorphic gene, the 
most explored polymorphism is a nonsynonymous SNP 
(rs1042522G>C) located in a proline–rich domain in 
Table 3: Association of DNA repair gene polymorphisms with anatomical and histological subtypes 
of gastric cancer
CARDIA GC HC Genotype GC Genotype Dominant model Recessive model Log-Additive model
Gen       db SNP ID A/a AA Aa aa AA Aa aa OR (95% CI)a FDRb OR (95% CI)a FDRb OR (95% CI)a FDRb
ERCC4 rs1799801 T/C 280 261 59 71 35 11 0.58 (0.38-0.88) 0.036 0.84 (0.40-1.77)  0.640 0.69 (0.49-0.97)  0.077
ERCC4   rs2238463 C/G 210 303 89 58 44 15 0.54 (0.35-0.81) 0.036 0.79 (0.42-1.49)  0.555 0.67 (0.49-0.92)  0.077
ERCC4  rs3136038 C/T 222 298 81 58 44 14 0.57 (0.38-0.87) 0.036 0.80 (0.42-1.53)  0.555 0.69 (0.50-0.96)  0.077
NON-CARDIA GC HC Genotype GC Genotype Dominant model Recessive model Log-Additive model
Gen db SNP ID A/a AA Aa aa AA Aa aa OR (95% CI)a FDRb OR (95% CI)a FDRb OR (95% CI)a FDRb
XPC  rs2228000 C/T 267 277 59 255 187 44 0.70 (0.55-0.90) 0.034 0.98 (0.64-1.48)  0.907 0.81 (0.67-0.98)  0.067
XRCC3 rs861528 G/A 350 205 33 218 176 27 1.45 (1.11-1.88)  0.034 1.21 (0.71-2.06)  0.626 1.31 (1.06-1.62)  0.067
POLG    rs176641 A/C 262 266 75 170 253 62 1.40 (1.09-1.81) 0.041 1.04 (0.72-1.50)  0.895 1.21 (1.00-1.46)  0.071
TP53 rs1042522 G/C 314 247 40 302 149 35 0.67 (0.52-0.87) 0.028 1.03 (0.76-1.97) 0.582 0.80 (0.65-0.98)  0.067
LIG3 rs2074522 G/A 509 89 2 393 81 12 1.37 (0.99-1.90) 0.084 7.94 (1.7-35.91) 0.027 1.46 (1.09-1.96)  0.067
BRIP1 rs4986764 C/T 224 270 107 197 230 56 0.87 (0.67-1.11) 0.315 0.59 (0.41-0.85) 0.037 0.81 (0.68- 0.97)  0.067
INTESTINAL GC HC Genotype GC Genotype Dominant model Recessive model Log-Additive model
Gen db SNP ID A/a AA Aa aa AA Aa aa OR (95% CI)a FDRb OR (95% CI)a FDRb OR (95% CI)a FDRb
ERCC5 rs17655 C/G 318 234 49 157 73 18 0.60 (0.43-0.82) 0.018 0.75 (0.40-1.39)  0.491 0.69 (0.53-0.89)  0.046
BRIP1 rs4986764 C/T 224 270 107 93 130 25 0.95 (0.69-1.31 0.809 0.48 (0.29-0.78)  0.026 0.82 (0.65-1.02)  0.157
DIFFUSE GC HC Genotype GC Genotype Dominant model Recessive model Log-Additive model
Gen db SNP ID A/a AA Aa aa AA Aa aa OR (95% CI)a FDRb OR (95% CI)a FDRb OR (95% CI)a FDRb
XRCC3 rs861528 G/A 350 205 33 66 73 13 2.11 (1.43-3.12) 0.001 1.75 (0.87-3.51)  0.239 1.75 (1.30-2.37) 0.003
XRCC3 rs861531 G/T 230 277 88 50 96 31 1.89 (1.26-2.84) 0.009 1.17 (0.72-1.89) 0.685 1.39 (1.07-1.81) 0.077
APEX1 rs1130409 T/G 155 300 145 62 78 38 0.61 (0.41-0.89) 0.044 0.76 (0.49-1.19)  0.333 0.74 (0.58-0.96)  0.078
TP53 rs1042522 G/C 314 247 40 113 53 12 0.64 (0.44-0.92) 0.046 1.01 (0.52-1.98) 0.723 0.77 (0.57-1.05) 0.185
HC, healthy control; GC, gastric cancer; A/a, major/minor alleles; OR, odds ratio; CI, confidence interval. 
aORs and 95% CIs were calculated by logistic regression analysis adjusted by gender, age, H. pylori infection, smoking, and family history of GC.
bQFDR-values obtained after applying the False Discovery Rate (FDR) test. QFDR-values < 0.05 are highlighted in bold.
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exon 4, which causes a proline–to–arginine substitution 
at codon 72 (Arg72Pro) [26]. Evidence indicates that this 
change in amino acid sequence affects the biochemical 
and biological functions of p53 [27], suggesting that the 
rs1042522 SNP may be relevant in cancer development. 
In this context, a number of case–control studies have 
reported the association of both the rs1042522G (Arg) 
and rs1042522C (Pro) variants with GC risk [28, 29]. 
Allele frequencies of rs1042522G>C differ notably 
among populations with values for the rs1042522C (Pro) 
variant ranging from ~63% in African Blacks to ~41% in 
Asians or ~17% in Swedish Saamis [30]. The relevance 
of these major ethnic and geographical variations in 
TP53 rs1042522 profiles are supported by two recent 
meta–analyses showing a significant association between 
the rs1042522C (Pro) variant and GC in Eastern Asian 
populations but not in Caucasians and South Americans 
[31, 32]. Similarly, some opposing associations have been 
reported among ethnicities when considering the location 
and histological subtypes of GC [33, 34]. However, and 
as the authors note, the specific meta–analysis performed 
in Caucasians comprised very few studies, which were 
limited by sample size, differed in methodology, or lacked 
information about other well-documented risk factors for 
GC, such as H. pylori infection, tobacco smoking, and 
diet. In line with our results, Pérez-Pérez et al. [28] and 
Zhang et al. [32] observed a significantly lower frequency 
of the rs1042522C (Pro) allele in GC patients compared 
to HCs. Moreover, an Italian study by De Feo et al. [35] 
showed a significant interaction between both TP53 
rs1042522C and rs1625895A minor alleles and protection 
against GC. 
The rs1042522 SNP is located in a proline–rich 
domain of the TP53 gene, which is essential for the 
regulation of p53–mediated apoptosis. In this regard, 
Marin et al. [36] first reported the contribution of 
rs1042522 allele variants to the induction of apoptosis in 
p53 mutant cells. According to the authors, p53 mutants 
encoded by the rs1042522G (Arg) allele are preferentially 
selected during tumorigenesis because they prevent tumor 
cells from apoptotic cell death. Moreover, Schneider-
Stock et al. [37] demonstrated that the rs1042522C (Pro) 
allele induces FasL/Fas–mediated apoptosis of tumor cells 
by cytotoxic T lymphocytes more effectively than does 
the rs1042522G (Arg) allele. Taken together, these results 
indicate a positive association between rs1042522G (Arg) 
Table 4: DNA repair gene haplotypes associated with gastric cancer risk
Gene SNPs Haplotype Frequency  HC Frequency GC OR (95% CI)a P-value
BRIP1 rs2048718 CAC 0.3730 0.4043 Reference
rs4968451 CAT 0.2021 0.1852 0.85 (0.65–1.1)  0.2203
rs4986764 TAC 0.1622 0.1609 0.91 (0.69–1.20)  0.5112
TCT 0.1117 0.0888 0.73 (0.53–0.99) 0.0459
TCC 0.0621 0.0712 1.07 (0.71–1.62)  0.7384
ERCC4 rs1799801 TGCC 0.5944   0.6408   Reference
rs1800067 CGGT 0.1857   0.1666   0.83 (0.66–1.03)  0.0927
rs2238463 CAGT 0.1167 0.1134 0.89 (0.69–1.16) 0.3962
rs3136038 TGGT  0.0790   0.0599   0.70 (0.50–0.96)  0.0291
ERCC5 rs1047768        CC 0.5330   0.5460   Reference
rs17655 TG 0.2335   0.1908   0.80 (0.66–0.98)  0.0350
TC 0.1908   0.2155   1.11 (0.89–1.37)  0.3500
TP53 rs1042522 GCG  0.4331 0.4417 Reference
rs1614984 GTG 0.2490 0.2939 1.13 (0.92–1.38)  0.2367
rs9894946 CTG 0.1347 0.1180 0.88 (0.67–1.14)  0.3292
CCA 0.1222 0.0847 0.68 (0.51–0.91)  0.0081
HC, healthy control; GC, gastric cancer; OR, odds ratio; CI, confidence interval. 
Haplotypes with frequencies > 0.05 are shown in the table.
aOdds ratios and 95% confidence intervals were calculated according to the additive genetic model taking as a reference the 
more common haplotype.
P-values < 0.05 are highlighted in bold.
Oncotarget35855www.impactjournals.com/oncotarget
status and reduction of apoptotic tumor cell death, an 
inference that is in line with the association of the TP53 
rs1042522C (Pro) variant and lower risk of GC observed 
in our population. 
A second polymorphism in the TP53 gene 
(rs9894946G>A), located in intron 10, was identified 
as a protective factor for GC development in our 
population. In line with these findings, Sprague et al. 
[38] reported a ~40% reduction in invasive breast cancer 
risk among women < 50 years carrying the rs9894946A 
allele. However, two other studies by García-Closas et 
al. [39] and Schildkraut et al. [40] found no evidence 
of association for rs9894946 and cancer development. 
Although variations in intronic structure have been 
proposed to influence cancer susceptibility via 
regulation of gene expression, gene splicing, or mRNA 
stability [41], the functional relevance of rs9894946 for 
p53 expression or function is still unknown. It is also 
plausible that this intronic polymorphism is in LD with 
other functional SNPs that may affect cancer risk. In 
our study, the TP53 rs1042522 and rs9894946 variants 
showed a moderate LD (D´ = 0.63, r2 = 0.22). Haplotype 
analysis did not provide additional information 
beyond individual SNP results, and haplotype TP53 
rs1042522C, rs1614984C, rs9894946A, containing both 
rs1042522C and rs9894946A protective alleles, was 
inversely associated with GC risk in our population. To 
our knowledge, this is the first study reporting the link 
between rs9894946 and risk of GC. Therefore, further 
studies with larger populations and different ethnic 
groups are required to conclusively assess the relevance 
of this SNP for GC development.
As noted, the nonsynonymous rs4986764C>T 
polymorphism (S919P) located in exon 18 of the BRIP1 
gene was associated with a lower risk of GC in our study. 
The BRIP1 (BRCA1-interacting protein 1) gene encodes 
a DEAH-box DNA helicase that directly interacts with 
the C–terminal domain of BRCA1. This bound complex 
is crucial for the normal double–strand break repair 
function of BRCA1 and checkpoint functions [42]. The 
BRIP1 rs2048718, rs4986764, and rs4968451 SNPs, 
all evaluated in our study, have been associated with 
susceptibility to meningioma [43], breast, and ovarian 
cancer [44]. However, no previous studies have addressed 
the contribution of BRIP1 gene variants to GC risk. In 
line with our results, Ma et al. [45] reported a protective 
effect of the rs4986764T allele against cervical cancer 
in a Chinese Han population, and individuals carrying 
the rs11079454T–rs4986763T–rs4986764T haplotype 
were less prone to cervical cancer. The same authors 
demonstrated that BRIP1 mRNA levels correlated 
with rs4986764 genotypes [46]. Based on the major 
anti–oncogenic role of the BRIP1 pathway, a low–level 
BRIP1 activation associated with the rs4986764C allele 
may lead to cancer development through an impaired 
DNA repair process. The scarcity of BRIP1 association 
studies highlights the need to characterize the genetic 
variation defined by the rs4986764 SNP and the functional 
consequences affecting BRIP1 expression or protein 
function. 
Similar to BRIP variants, knowledge is very 
limited about the influence of LIG3 (DNA ligase 3) gene 
polymorphisms to GC cancer susceptibility. LIG3 is one 
of three mammalian genes encoding DNA ligases I, III, 
and IV. These proteins catalyze the joining of DNA ends 
although they each have a distinct functional significance 
[47]. DNA Lig III participates in the BER pathway and 
DNA single strand break repair by forming a stable 
complex with XRCC1. Polymorphisms in the LIG3 
gene have been associated with increased risk of several 
cancers such as colon [48], lung [49], and esophageal 
cancer [50]. In the present study, the rare allele A of the 
intronic rs2074522 variant (MAF: 0.089) was significantly 
associated with a higher overall risk of GC. In contrast 
Table 5: Logistic regression analysis environmental and genetic factors associated with GC risk
Factor OR (95% CI) P-value
Gender 0.98 (0.72–1.33) 0.892
Age 1.00 (0.99–1.01) 0.533
Infection with H. pylori CagA+ 1.99 (1.55–2.54) 0.000
Tobacco (being current smoker) 1.77 (1.22–2.57) 0.003
Positive family history of GC 2.87 (1.85–4.45) 0.000
TP53 rs1042522 allele C (dominant model) 0.76 (0.58–0.98) 0.043
TP53 rs9894946 allele A (log-additive model)    0.73 (0.56–0.96) 0.027
LIG3 rs2074522 allele A (recessive model) 5.67 (1.24–25.95) 0.025
BRIP1 rs4986764 allele T (recessive model) 0.55 (0.38–0.78) 0.001
GC, gastric cancer; OR, odds ratio; 95% CI, 95% confidence interval. 
P- values < 0.05 are highlighted in bold.
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with our findings, patients homozygous for the rs2074522 
A allele were less prone to developing pancreatic cancer in 
a US study by Li et al. [51]. In addition to tissue–specific 
factors, these discrepant results could be explained by 
the low frequency of the rs2074522 AA genotype among 
Caucasians. In our population, the frequencies of the 
rs2074522 AA genotype in healthy individuals (0.33%) 
and GC patients (2.15%) were similar to those reported in 
European populations. Therefore, although QFDR values for 
LIG3 rs2074522 retained significance in several genetic 
models, our results should be interpreted with caution and 
confirmed in future studies with larger sample sizes. 
Stratified SNP analysis by tumor location (cardia/
non–cardia) and histological type of GC (intestinal/
diffuse) revealed some additional significant associations. 
Of interest, three SNPs (rs1799801T>C, rs2238463C>G, 
and rs3136038C>T) located in the NER gene ERCC4 
(excision repair cross-complementary group 4) and in 
strong LD with each other were inversely associated with 
cardia GC risk. The ERCC4 gene, also known as XPF, 
is a key component of the NER pathway that also plays 
an important role in removal of DNA interstrand cross–
links and DNA double-strand breaks [52]. Information 
concerning the relevance of ERCC4 gene variants to 
GC susceptibility is very limited. To date, only studies 
performed in Asians have been published. Two Chinese 
reports by Gong et al. [53] and He et al. [54] found no 
association between risk of GC and rs6498486T>G, a 
tag SNP located in the promoter region which tags the 
rs3136038 SNP evaluated in our study. Similarly, Zhang 
et al. [55] observed a non–significantly decreased risk in 
patients carrying the rs180067 G or rs1799801 T alleles. 
In agreement with these results, we found no significant 
associations between ERCC4 variants and overall risk of 
GC after FDR multiple test corrections. However, carriers 
of the minor rs1799801C, rs2238463G, or rs3136038T 
alleles had a significantly lower risk of developing cardia 
GC. Functional studies by Shi et al. [56] reported higher 
XPF transcript expression levels in subjects carrying the 
rs1799801 CC genotype compared to those carrying the 
wild T allele, a finding that is biologically plausible with 
the protective effect of the rs1799801 C variant observed 
in our study. 
When considering the histological type of tumor, the 
most remarkable associations were observed in the DSBR 
gene XRCC3 (X-ray repair cross complementing 3), 
with the rs861528G>A and rs861531G>T intronic variants 
being associated with a higher risk of diffuse GC. The 
XRCC3 gene encodes a member of the RecA/Rad51–
related protein family that functions in homologous 
recombination repair of DNA double–strand breaks [57]. 
The most explored polymorphism is a C>T transition 
in exon 7 (rs861539), which causes a threonine–to–
methionine substitution at codon 241 (Thr241Met) [58]. 
In agreement with a recent meta–analysis [59], we found 
no evidence of association for rs861539 and GC risk. 
However, FDR values (QFDR = 0.054) showed a borderline 
increased risk of diffuse GC in patients carrying the 
T allele. Unlike rs861539, very few studies have been 
published on rs861528/rs861531 variants and cancer 
susceptibility, most of them reporting inconclusive results. 
In the current work, rs861528 and rs861531 showed 
a moderate–high LD (D´ = 0.97, r2 = 0.55). Of interest, 
the rs861531 SNP was highly linked with the functional 
rs861539 Thr241Met variant (D’ = 0.99, r2 = 0.94), with 
lower values for rs861528 and rs861539 (D’ = 0.90, 
r2 = 0.47). Despite the potential influence of intronic 
variants in gene regulation, the functional relevance of 
the susceptible intronic rs861528 and rs861531 SNPs 
remains unknown. Taken together, these major differences 
in genotype distribution and environmental exposures 
observed in our study among GC subtypes reveal the 
marked heterogeneity of GC and highlight the need to 
investigate each type separately when possible. Because 
GC subtypes may result from different pathogenic 
mechanisms, this strategy of refining the phenotype may 
improve power for detecting genetic associations.
Finally, we also examined whether the contribution 
of DNA repair genes to GC risk could be modified by 
other risk factors identified in our study, such as H. pylori 
infection, smoking, and positive family history of GC. 
Whereas smoking and family history of GC showed 
no effect in modifying the contribution of DNA repair 
polymorphisms to GC, a significant association between 
the previously reported TP53 rs1042522, rs9894946, 
LIG3 rs2074522, and BRIP1 rs4986764 variants and 
overall GC risk was observed among H. pylori infected 
patients. After FDR correction, only TP53 rs1042522 
(P72R) remained significant, although tests for interaction 
between rs1042522 and H. pylori infection did not reach 
statistical significance. Taking into account that none of 
the SNPs analyzed in our study were associated with 
prevalence of infection or CagA/VacA strains, our findings 
suggest that TP53 rs1042522 is likely to be associated 
with GC development after bacterial infection occurs and 
not with susceptibility to H. pylori infection per se. In 
this context, mutants of p53 protein have been recently 
reported as potential markers of H. pylori–associated 
gastric carcinogenesis [60]. Moreover, inflammation 
induced by H. pylori infection results in the generation 
of DNA–damaging reactive oxygen and nitrogen species 
in gastric epithelial cells [61]. Under normal conditions, 
there is a balance between DNA damage and DNA repair; 
however, reduced DNA repair capacity associated with 
gene variants and increased DNA damage generated by 
H. pylori infection may alter this status and give rise 
to the accumulation of DNA damage and consequently 
cancer development. Unfortunately, the scarcity of studies 
[53, 62, 63] addressing this issue makes it very difficult 
to conclude whether H. pylori infection has any effect on 
the relationship between DNA repair gene variants and 
GC risk. 
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Our study has several strengths and limitations. A 
comprehensive analysis of 123 SNPs in candidate DNA 
repair genes, some of them not previously evaluated 
for the risk of GC, was carried out in a homogeneous 
population of Spanish Caucasian subjects (603 HCs and 
603 GC patients). To our knowledge, the current study is 
the first to show a significant effect of TP53 rs9894946, 
LIG3 rs2074522, and BRIP1 rs4986764 variants on GC 
susceptibility. Moreover, additional associations with 
specific anatomic locations and histological subtypes 
of GC were observed. The fact that these associations 
remained significant after FDR multiple test corrections 
indicates that our results may not be a chance finding. 
However, some limitations also should be considered. 
In particular, although our study is one of the largest 
performed in Western populations, the sample size 
limited the power to detect small ORs, mainly in low–
frequency variant polymorphisms. Taking into account 
the prevalence of the SNPs evaluated in our population 
and setting an a value of 0.05, the study had a power of 
85% to detect ORs > 1.45 or < 0.70 except for the less 
prevalent variants (MAF: 0.05–0.10), with a power of 
80% to observe OR > 1.97 in the whole data set. As a 
result, it is possible that we could have missed minor 
statistical differences, especially when subgroup analyses 
and assessment of gene–environment interactions were 
performed.
In summary, we can conclude that the TP53 
(rs1042522, rs9894946G), LIG3 (rs2074522G), and BRIP1 
(rs4986764) variants are involved in the susceptibility 
to GC, particularly in subjects infected by H. pylori. 
Like many other complex diseases, GC is the result of a 
multifactorial interplay involving environmental, lifestyle, 
and host genetic factors. Because the magnitude of each 
etiologic factor might differ among populations, larger 
studies in different geographic areas and ethnic groups 
are warranted to elucidate the contribution of DNA repair 
gene polymorphisms and their interactions with other risk 
factors in the susceptibility to GC and phenotype. 
MATERIALS AND METHODS
Subjects
A total of 684 Spanish Caucasian patients with 
primary GC diagnosed in a network of 16 general hospitals 
in Spain, from May 2003 to December 2010, were invited to 
take part in the study. Patients with gastric neoplasms other 
than adenocarcinoma, secondary or recurrent GC, previous 
history of other malignancies, or refusal to participate were 
excluded. Finally, 646 GC patients were initially selected 
as cases for this study. Gastric tumors were classified 
according to their histological type [3] as intestinal, 
diffuse, or indeterminate, and by anatomical location 
as proximal and non–cardia or distal GC. Information 
regarding demographic characteristics and potential risk 
factors including smoking habits and family history of GC 
were collected by a questionnaire administered by trained 
personnel as previously described [64]. 
The control group consisted of 646 Spanish, 
Caucasian, cancer–free volunteers with no previous 
history or symptoms of gastrointestinal disease, matched 
by gender, age (±5 years), and area of residence. Most 
controls were blood donors and individuals recruited from 
the outpatient clinical services in the same hospitals as 
cases. Eligible controls were also interviewed with the 
same standard questionnaire designed for patients. 
Following completion of the interview, 10 ml of 
peripheral blood was collected from each participant 
for DNA extraction and serological study of H. pylori 
infection. Once processed, whole blood and serum 
samples were aliquoted and stored at –80°C until analysis. 
All patients and controls gave written informed consent 
to the study protocol, which was approved by the Ethical 
Committee of the Hospitals.  
Helicobacter pylori diagnosis
The presence of H. pylori infection was determined 
in GC patients by urease test (CLO-test; Delta West 
Ltd., Canning Vale, Bentley, Australia) and histological 
examination of biopsies taken at the antrum and corpus of 
the stomach during the endoscopic procedure. In addition, 
GC patients and controls were analyzed to determine in 
serum the presence of H. pylori infection and antibodies 
to CagA and/or to VacA antigens by western blot analysis 
(Bioblot Helicobacter, Izasa, Barcelona, Spain). This test 
for H. pylori infection and CagA/VacA antibodies has 
been previously validated in our area [65]. GC patients 
were considered positive for bacterial infection if any of 
the three tests was positive. However, for statistical and 
data analysis, only information related to western blot 
analysis in serum samples from CG patients and controls 
was considered.
SNP selection and genotyping
All DNA repair gene polymorphisms evaluated in 
our study were selected from the NCBI data base (http://
www.ncbi.nlm.nih.gov/snp), Genome build 38.p2. The 
panel of SNPs was chosen based on three criteria: (1) a 
reported prevalence of at least 5% for the less frequent 
allele among Caucasians; (2) potential functional 
consequences or (3) published evidence of an association 
with different types of cancer. We assessed a total of 
123 SNPs located in 52 genes related to different DNA 
repair pathways (Supplementary Table 12). The selected 
panel comprised 18 SNPs located in genes involved in 
BER genes (PARP1, OGG1, POLB, POLG, POLI, FEN1, 
APEX1, NEIL1, LIG1, LIG3, XRCC1, PCNA), 26 SNPs 
located in NER genes (ERCC1, ERCC2, ERCC3, ERCC4, 
ERCC5, ERCC6, XPA, XPC, POLE), 29 SNPs located 
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in MMR genes (MUTHY, EXO1, MSH2, MSH3, MSH6, 
MLH1, MLH3, PMS2), 38 SNPs located in DSBR genes 
by homologous recombination (XRCC2, XRCC3, BRCA1, 
BRCA2, BRIP1, RAD51, RAD51B, RAD52, RAD54L, 
MRE11A) or non–homologous end joining (XRCC4, 
XRCC5, XRCC6, RAD50, WRN, NES1, LIG4), 8 SNPs 
located in cell cycle checkpoint genes (ATM, ATR, TP53), 
and 4 SNPs located in genes (MGMT, ALKBH2, ALKBH3) 
coding for proteins involved in direct repair of DNA 
damage produced by alkylating agents.
Genomic DNA from patients and controls was 
extracted from ethylenediamine-tetraacetic acid–
preserved whole blood using the QIAamp DNA Blood 
Mini extraction kit (Qiagen, Izasa, Barcelona, Spain). 
Genotyping was performed at the Spanish National 
Genotyping Centre (CEGEN-Santiago de Compostela) 
using the Illumina Veracode Platform (Illumina, 
Eindhoven, The Netherlands). As a quality control, 
5% of samples, including internal controls by CEGEN, 
were analyzed in duplicate with a concordance rate of 
100% for all assays. Among the 123 SNPs evaluated, 15 
SNPs were excluded from the analysis due to failure of 
genotyping (MUTYH rs3219484, MSH2 rs2303426, ATR 
rs2227928, MSH3 rs184967, ERCC6 rs2228526, POLE 
rs5744751, RAD51B rs10483813, XRCC1 rs25489, 
ERCC1 rs11615, XRCC6 rs132788), SNP call rate < 
90% (BRCA1 rs3737559, MSH2 rs1863332, ERCC6 
rs2228524, MGMT rs12917), or monomorphism (POLB 
rs12678588). Samples in which more than 20% of the 
SNPs failed genotyping were excluded (cases = 29, HCs 
= 15). In this study, genotype completion on genomic 
DNA samples exceeded 95%. Finally, after excluding 42 
unmatched samples, 108 SNPs in 1206 subjects (603 GC 
patients and 603 HCs) were successfully genotyped and 
available for analysis.
Statistical analysis
Genotype frequencies for each DNA repair gene 
polymorphism among controls were tested for Hardy–
Weinberg equilibrium by a Chi-square (χ2) test with one 
degree of freedom (Supplementary Table 12). Genotype 
and allele frequencies between CG patients and controls 
were compared using the χ2 test with Yates’ correction or 
Fisher’s exact test. The magnitude of the association of 
each polymorphism was estimated by ORs and 95% CIs 
using the SNPassoc package implemented in R. Analyses 
were performed using codominant, dominant, recessive, 
and log-additive genetic models. In addition, unconditional 
logistic regression analysis was conducted to quantify the 
influence of both genetic and environmental factors for 
GC as dependent variable. A variable was entered in the 
model if the significance level of its coefficient was less 
than 0.05 and was removed if it was greater than 0.10. 
Categorical variables included in the model were codified 
as dummy variables. For all tests, a two–sided P value 
< 0.05 was considered statistically significant. To address 
the issue of adjustment for multiple testing, the FDR test 
using a Benjamini–Hochberg method was applied [66]. 
Finally, comparison of common haplotype frequencies 
(> 0.05) in each gene block between GC patients and 
controls was performed. Estimated haplotype frequencies 
and LD coefficients (D´ and r2) were calculated using the 
haplo.stats package implemented in R. For each marker, 
the more common haplotype was used as the reference 
category. The statistical analyses were performed using 
SPSS 23.0 for Windows (SPSS Ibérica, Madrid, Spain).
Taking into account the prevalence of the analyzed 
SNPs in our population, the size of the study was sufficient 
to detect ORs > 1.45 or < 0.70 with a power of 80% and 
a a value of 0.05. For the less prevalent polymorphisms 
(MAF: 0.05–0.10), the study had a power of 80% to 
detect an OR of > 1.97 in the whole data set. All power 
calculations were performed using the program Epidat 4.1.
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Supplementary Table 1: Demographic and clinical characteristics of HCs and GC patients 





ORs (95% CI) P Value Non–Cardia GC 
n = 486
ORs (95% CI) P Value
Age yrs ± SD (range) 70.17 ± 12.32 69 ± 11.06 0.99 (0.98–1.01) 0.67 70.59 ± 12.55 1 (0.99–1.01) 0.69
(30–96) (30–91) (30–96)
Gender 413 M (68.5%) 102 M (87.2%) 311 M (64%)
190 F (31.5%) 15 F (12.8%) 3.15 (1.78–5.57) < 0.0001 175 F (36%) 0.83 (0.64–1.07) 0.14
Cigarette smoking
       Never 311/585 (53.2%) 33/114 (28.9%) Reference 258/468 (55.1%) Reference
       Former 184/585 (31.4%) 53/114 (46.5%) 2.71 (1.69–4.35) < 0.0001 101/468 (21.6%) 0.71 (0.53–0.95) 0.02
       Current smoker 90/585 (15.4%) 28/114 (24.6%) 2.93 (1.68–5.11) 0.0002 109/468 (23.3%) 1.35 (0.97–1.88) 0.07
H.  pylori + 364 (60.4%) 67/109 (61.5%) 1.01 (0.72–1.44) 0.93 310/447 (69.3%) 1.49 (1.15–1.94) 0.002
       CagA+ 253 (41.9%) 45/109 (41.3%) 0.97 (0.68–1.32) 0.96 280/447 (62.6%) 2.32 (180–2.98) < 0.0001
       VacA+ 237 (39.3%) 38/109 (34.9%) 0.82 (0.54–1.27) 0.39 185/447 (41.4%) 1.09 (0.85–1.40) 0.49





ORs (95% CI) P Value Diffuse GC 
n = 178
ORs (95% CI) P Value
Age yrs ± SD (range) 70.17 ± 12.32 72.82 ± 10.73 1.02 (1.01–1.03) 0.004 67.34 ± 14.32 0.98 (0.98–0.99) 0.005
(30–96) (33–92) (30–96)
Gender 413 M (68.5%) 167 M (66.8%) 101 M (56.7%)
190 F (31.5%) 83 F (33.2%) 0.98 (0.72–1.36) 0.94 77 F (43.3%) 0.58 (0.41–0.82) 0.002
Cigarette smoking
       Never 311/585 (53.2%) 134/240 (55.8%) Reference 102/171 (59.6%) Reference
       Former 184/585 (31.4%) 65/240 (27.1%) 0.82 (0.58–1.16) 0.29 40/171 (23.4%) 0.66 (0.44–1.00) 0.06
       Current smoker 90/585 (15.4%) 41/240 (17.1%) 1.06 (0.69–1.61) 0.83 29/171 (17%) 0.98 (0.61–1.58) 1
H.  pylori + 364 (60.4%) 158/231 (68.4%) 1.47 (1.06–2.03) 0.02 123/159 (77.3%) 2.17 (1.44–3.26) < 0.0001
       CagA+ 253 (41.9%) 143/231 (61.9%) 2.25 (1.65–3.07) < 0.0001 109/159 (68.5%) 3.02 (2.08–4.37) < 0.0001
       VacA+ 237 (39.3%) 100/231 (43.3%) 1.21 (0.88–1.64) 0.23 68/159 (42.8%) 1.11 (0.78–1.59) 0.56
Family history of GC 33/539 (6.1%) 42/222 (18.9%) 3.58 (2.20–5.82) < 0.0001 23/159 (14.5%) 2.60 (1.47–4.56) 0.001
HCs, healthy controls; GC, gastric cancer; n, number of individuals; OR, odds ratio; CI, confidence interval; SD, standard deviation; M, male; F, female.  
OR and 95% CI values adjusted by sex and age. P values < 0.05 are highlighted in bold.
Supplementary Table 2: Genotype frequencies of DNA repair gene polymorphisms in gastric cancer patients and healthy controls. 
Anatomic location Histological type 
Cardia GC Distal GC Intestinal GC Diffuse GC 
 Healthy Controls n = 603 
Gastric Cancer patients 
n = 603 
n = 117 n = 486 n = 250 n = 178 
db SNP ID Gene A/a AA Aa aa N MAF AA Aa aa N MAF AA Aa aa MAF AA Aa aa MAF AA Aa aa MAF AA Aa aa MAF 
rs10079641 MSH3 C/G 472 117 4 593 0.105 473 110 6 589 0.104 94 22 ― 0.095 379 88 6 0.106 195 47 3 0.108 139 33 2 0.106 
rs1042522 TP53 G/C 314 247 40 601 0.272 372 192 39 603 0.224 70 43 4 0.218 302 149 35 0.225 150 80 20 0.240 113 53 12 0.216 
rs1047768 ERCC5 C/T 204 284 113 601 0.424 221 274 108 603 0.406 47 50 20 0.385 174 224 88 0.412 95 106 49 0.408 61 89 28 0.407 
rs1047840 EXO1 G/A 217 290 94 601 0.398 232 273 84 589 0.374 42 57 16 0.387 190 216 68 0.371 100 114 29 0.354 66 78 30 0.397 
rs1048771 RAD54L C/T 465 125 5 595 0.113 413 108 10 531 0.121 88 18 1 0.093 325 90 9 0.127 160 53 5 0.144 121 29 4 0.120 
rs1051677 XRCC5 T/C 500 98 4 602 0.088 487 113 2 602 0.097 94 23 ― 0.098 393 90 2 0.097 201 46 2 0.100 146 32 ― 0.090 
rs1051685 XRCC5 A/G 493 98 10 601 0.098 489 110 4 603 0.098 90 27 ― 0.115 399 83 4 0.094 201 47 2 0.102 149 27 2 0.087 
rs1052133 OGG1 C/G 367 210 26 603 0.217 381 195 27 603 0.206 74 37 6 0.209 307 158 21 0.206 153 83 14 0.222 118 53 7 0.188 
rs1059262 ALKBH2 T/G 398 181 22 601 0.187 417 162 23 602 0.173 81 30 6 0.179 336 132 17 0.171 174 66 10 0.172 129 43 5 0.150 
rs1060915 BRCA1 T/C 272 268 62 602 0.326 248 291 62 601 0.345 44 61 12 0.363 204 230 50 0.341 107 115 26 0.337 73 91 14 0.334 
rs11226 RAD52 C/T 211 281 96 588 0.402 165 253 112 530 0.450 28 56 23 0.477 137 197 89 0.443 74 99 45 0.433 42 79 33 0.471 
rs1130409 APEX1 T/G 155 300 145 600 0.492 180 282 139 601 0.466 33 53 30 0.487 150 229 106 0.455 75 121 53 0.456 62 78 38 0.433 
rs1136410 PARP1 T/C 459 138 6 603 0.124 438 154 11 603 0.146 85 30 2 0.145 353 124 9 0.146 187 56 7 0.140 122 54 2 0.163 
rs13180316 XRCC4 G/A 317 237 43 597 0.271 324 223 50 597 0.271 63 42 12 0.282 261 181 38 0.268 136 89 21 0.266 85 75 16 0.304 
rs13181 ERCC2 T/G 275 254 74 603 0.333 258 261 83 602 0.355 52 43 22 0.372 206 218 61 0.351 108 107 34 0.351 75 80 23 0.354 
rs1346044 WRN T/C 360 207 34 601 0.229 374 202 22 598 0.206 79 33 3 0.170 295 169 19 0.214 158 85 6 0.195 104 64 9 0.232 
rs144848 BRCA2 T/G 305 256 39 600 0.278 295 256 50 601 0.296 59 49 9 0.286 236 207 41 0.299 111 116 23 0.324 94 68 14 0.273 
rs1478485 XRCC4 C/T 221 285 95 601 0.395 196 312 94 602 0.415 39 56 22 0.427 157 256 72 0.412 78 135 37 0.418 61 94 22 0.390 
rs1540354 MLH1 T/A 469 120 13 602 0.121 478 111 11 600 0.111 95 20 2 0.103 383 91 9 0.113 192 50 6 0.125 144 30 3 0.102 
rs1614984 TP53 C/T 227 273 88 588 0.382 183 252 90 525 0.411 31 57 18 0.439 152 195 72 0.405 72 97 44 0.434 62 69 23 0.373 
rs1618536 ERCC2 G/A 162 264 155 581 0.494 155 245 124 524 0.470 30 52 25 0.477 125 193 99 0.469 60 101 52 0.481 46 72 34 0.461 
rs1650697 MSH3 C/T 322 221 44 587 0.263 307 185 37 529 0.245 53 47 7 0.285 254 138 30 0.235 134 72 12 0.220 91 50 12 0.242 
rs174538 FEN1 G/A 289 242 57 588 0.303 259 214 51 524 0.302 45 53 9 0.332 214 161 42 0.294 116 83 17 0.271 73 61 16 0.310 
rs175080 MLH3 G/A 198 281 120 599 0.435 186 293 116 595 0.441 34 63 20 0.440 152 230 96 0.441 74 127 47 0.446 61 78 36 0.429 
rs1760944 APEX1 C/A 212 271 72 555 0.374 207 253 75 535 0.377 37 49 15 0.391 170 204 60 0.373 84 117 24 0.367 56 68 29 0.412 
rs17655 ERCC5 C/G 318 234 49 601 0.276 350 214 36 600 0.238 68 45 4 0.226 282 169 32 0.241 157 73 18 0.220 95 73 10 0.261 
rs176641 POLG A/C 262 266 75 603 0.345 221 302 79 602 0.382 51 49 17 0.355 170 253 62 0.389 88 130 31 0.386 62 99 17 0.374 
rs1776148 EXO1 G/A 227 282 91 600 0.387 223 295 82 600 0.382 45 56 15 0.371 178 239 67 0.385 95 122 33 0.376 54 95 27 0.423 
rs1799793 ERCC2 G/A 292 249 62 603 0.309 277 252 73 602 0.331 58 40 19 0.333 219 212 54 0.330 113 110 26 0.325 81 76 21 0.331 
rs1799794 XRCC3 A/G 334 225 42 601 0.257 342 224 34 600 0.243 67 44 6 0.239 275 180 28 0.244 144 86 19 0.249 100 72 4 0.227 
rs1799796 XRCC3 A/G 338 230 31 599 0.244 359 217 27 603 0.225 72 39 6 0.218 287 178 21 0.226 142 99 9 0.234 112 56 10 0.213 
rs1799801 ERCC4 T/C 280 261 59 600 0.316 306 239 57 602 0.293 71 35 11 0.244 235 204 46 0.305 118 106 25 0.313 85 78 15 0.303 
rs1799955 BRCA2 A/G 358 218 27 603 0.226 354 230 18 602 0.221 66 47 4 0.235 288 183 14 0.218 152 91 6 0.207 102 71 5 0.228 
rs1799966 BRCA1 A/G 267 271 65 603 0.333 244 291 60 595 0.345 44 62 11 0.359 200 229 49 0.342 104 114 26 0.340 73 90 14 0.333 
rs1799977 MLH1 A/G 272 258 73 603 0.335 265 278 60 603 0.330 41 58 18 0.402 224 220 42 0.313 107 121 22 0.330 91 74 13 0.281 
rs1800067 ERCC4 G/A 458 129 7 594 0.120 465 124 6 595 0.114 97 19 1 0.090 368 105 5 0.120 187 54 3 0.123 135 40 1 0.119 
rs1800389 WRN T/C 328 224 49 601 0.268 347 211 40 598 0.243 65 46 5 0.241 282 165 35 0.244 146 81 21 0.248 100 63 14 0.257 
rs1800734 MLH1 G/A 349 210 40 599 0.242 341 218 37 596 0.245 71 38 7 0.224 270 180 30 0.250 141 93 11 0.235 98 65 14 0.263 
rs1800935 MSH6 T/C 310 244 43 597 0.276 282 276 42 600 0.300 54 55 8 0.303 228 221 34 0.299 116 110 22 0.310 87 79 12 0.289 
rs1800975 XPA G/A 282 256 65 603 0.320 296 248 59 603 0.303 47 50 20 0.385 249 198 39 0.284 128 102 20 0.284 96 69 13 0.267 
rs1801406 BRCA2 A/G 284 264 55 603 0.310 284 283 32 599 0.290 52 58 7 0.308 232 225 25 0.285 122 113 13 0.280 80 88 8 0.295 
rs1801516 ATM G/A 447 146 9 602 0.136 433 157 12 602 0.150 84 31 2 0.150 349 126 10 0.151 174 68 7 0.165 126 49 3 0.154 
rs1802904 ATR A/G 459 138 6 603 0.124 446 140 13 599 0.139 85 30 2 0.145 361 110 11 0.137 176 68 5 0.157 138 33 5 0.122 
rs1805386 LIG4 T/C 412 173 15 600 0.169 415 172 13 600 0.165 79 31 7 0.192 336 141 6 0.158 169 77 3 0.167 130 44 3 0.141 
rs1805388 LIG4 C/T 442 136 10 588 0.133 383 131 11 525 0.146 68 33 3 0.188 315 98 8 0.135 157 56 5 0.151 121 28 3 0.112 
rs1805794 NBS1 C/G 310 233 59 602 0.292 300 241 61 602 0.301 51 53 12 0.332 249 188 49 0.294 140 81 29 0.278 91 71 16 0.289 
rs1981928 MSH2 T/A 315 241 45 601 0.275 307 258 34 599 0.272 56 51 10 0.303 251 207 24 0.265 128 108 11 0.263 90 76 11 0.277 
rs2020911 MSH6 A/T 253 268 80 601 0.356 255 274 74 603 0.350 43 60 14 0.376 212 214 60 0.344 106 112 32 0.352 74 80 24 0.360 
rs2040639 XRCC2 G/A 175 291 133 599 0.465 194 284 117 595 0.435 35 56 24 0.452 159 228 93 0.431 79 120 47 0.435 58 81 37 0.440 
rs2048718 BRIP1 C/T 189 282 105 576 0.427 202 281 100 583 0.413 44 56 9 0.339 158 225 91 0.429 79 117 45 0.429 56 85 34 0.437 
rs20580 LIG1 C/A 171 286 143 600 0.477 155 295 150 600 0.496 29 59 28 0.496 127 236 121 0.494 68 124 56 0.476 51 84 43 0.478 
rs2074522 LIG3 G/A 509 89 2 600 0.078 496 94 13 603 0.100 103 13 1 0.064 393 81 12 0.108 207 38 5 0.095 145 30 3 0.101 
rs2075685 XRCC4 G/T 193 296 113 602 0.434 174 319 109 602 0.446 32 61 24 0.466 142 258 85 0.441 71 135 44 0.446 54 99 24 0.415 
rs207906 XRCC5 G/A 464 127 12 603 0.125 466 127 9 602 0.12 83 33 1 0.150 383 94 8 0.113 198 48 3 0.108 140 34 4 0.118 
rs2228000 XPC C/T 267 277 59 603 0.328 314 235 54 603 0.284 59 48 10 0.291 255 187 44 0.283 134 94 22 0.276 91 72 15 0.287 
rs2228001 XPC A/C 220 284 94 598 0.395 207 231 92 530 0.392 42 43 22 0.407 165 188 70 0.388 82 97 38 0.399 58 70 26 0.396 
rs2228006 PMS2 G/A 436 140 20 596 0.151 371 146 13 530 0.162 69 34 4 0.196 302 112 9 0.154 154 57 7 0.163 108 44 1 0.150 
rs2238463 ERCC4 C/G 210 303 89 602 0.400 250 275 76 601 0.355 58 44 15 0.316 192 231 61 0.365 93 122 34 0.382 73 84 20 0.350 
rs2252775 RAD50 A/C 370 213 18 601 0.207 367 214 20 601 0.211 71 42 4 0.214 296 172 16 0.211 147 92 9 0.222 114 59 5 0.194 
rs2272615 POLB A/G 459 125 11 595 0.124 464 120 11 595 0.119 92 23 2 0.115 372 97 9 0.120 197 44 6 0.113 128 43 3 0.141 
rs2286940 MLH1 C/T 170 280 149 599 0.482 154 308 139 601 0.488 31 61 25 0.474 129 247 108 0.478 67 125 57 0.480 47 92 38 0.475 
rs2303428 MSH2 T/C 495 98 9 602 0.095 476 120 6 602 0.110 84 32 1 0.145 392 88 5 0.101 204 41 4 0.098 138 39 1 0.115 
rs2308321 MGMT A/G 476 90 11 577 0.097 468 97 2 567 0.089 88 18 ― 0.085 380 79 2 0.090 193 40 ― 0.085 136 33 1 0.103 
rs2345060 PMS2 A/G 334 229 38 601 0.254 365 206 31 602 0.223 74 37 6 0.209 291 169 25 0.226 151 84 15 0.228 103 66 8 0.232 
rs2348244 MSH6 T/C 448 144 11 603 0.138 471 127 4 602 0.112 84 32 1 0.145 387 95 3 0.104 202 46 2 0.100 136 40 1 0.119 
rs238406 ERCC2 G/T 162 282 159 603 0.498 169 268 166 603 0.498 31 55 31 0.500 138 213 135 0.497 69 116 65 0.492 53 76 49 0.489 
rs2434470 ALKBH3 C/G 349 217 35 601 0.239 370 200 27 597 0.213 67 41 8 0.246 303 159 19 0.205 152 88 9 0.213 107 57 10 0.221 
rs2440 XRCC5 C/T 185 301 116 602 0.443 177 307 117 601 0.450 38 56 23 0.436 139 251 94 0.454 70 136 42 0.444 51 87 40 0.469 
rs25487 XRCC1 G/A 230 271 102 603 0.394 254 260 89 603 0.363 53 47 17 0.346 201 213 72 0.367 106 104 40 0.368 72 78 28 0.376 
rs26279 MSH3 A/G 287 243 70 600 0.319 281 254 68 603 0.323 61 47 9 0.278 220 207 59 0.334 112 104 34 0.344 84 77 17 0.312 
rs26779 MSH3 G/A 203 301 95 599 0.410 239 276 87 602 0.374 40 63 14 0.389 199 213 73 0.370 103 112 34 0.361 74 71 33 0.385 
rs293794 OGG1 T/C 410 168 19 597 0.173 401 190 10 601 0.175 76 40 1 0.179 325 150 9 0.174 178 68 4 0.152 110 62 4 0.199 
rs3136038 ERCC4 C/T 222 298 81 601 0.383 258 277 66 601 0.340 58 44 14 0.310 200 233 52 0.347 98 123 28 0.359 75 84 19 0.343 
rs3136228 MSH6 T/G 256 274 68 598 0.343 242 280 77 599 0.362 50 51 16 0.355 192 229 61 0.364 98 114 36 0.375 73 84 20 0.350 
rs3212948 ERCC1 C/G 250 262 89 601 0.366 243 268 85 596 0.367 50 55 12 0.338 193 213 73 0.375 99 112 36 0.372 72 73 30 0.380 
rs3212961 ERCC1 C/A 468 128 6 602 0.116 466 125 12 603 0.124 88 26 3 0.137 378 99 9 0.120 190 54 6 0.132 138 37 3 0.121 
rs3212986 ERCC1 G/T 329 223 43 595 0.260 294 200 37 531 0.258 65 37 5 0.220 229 163 32 0.268 122 84 12 0.248 80 59 15 0.289 
rs3213245 XRCC1 T/C 230 281 90 601 0.384 227 265 110 602 0.403 48 43 26 0.406 179 222 84 0.402 93 110 46 0.406 70 78 30 0.388 
rs3218536 XRCC2 G/A 486 113 3 602 0.099 483 115 5 603 0.104 100 15 2 0.080 383 100 3 0.109 193 56 1 0.116 142 34 2 0.107 
rs3219489 MUTYH G/C 309 248 43 600 0.278 318 242 32 592 0.258 67 40 8 0.243 251 202 24 0.262 124 104 15 0.276 92 76 8 0.261 
rs3626 PCNA G/C 455 135 12 602 0.132 460 136 7 603 0.124 88 29 ― 0.124 372 107 7 0.124 193 55 2 0.118 135 40 3 0.129 
rs3730668 POLI G/T 186 314 98 598 0.426 199 288 107 594 0.423 36 49 29 0.469 163 239 78 0.411 84 115 46 0.422 60 92 25 0.401 
rs3793784 ERCC6 C/G 200 282 117 599 0.431 211 288 101 600 0.408 45 48 24 0.410 166 240 77 0.408 95 105 48 0.405 57 96 24 0.407 
rs4150416 ERCC3 T/G 269 273 59 601 0.325 301 255 47 603 0.289 51 61 5 0.303 250 194 42 0.286 132 94 24 0.284 86 79 13 0.295 
rs4150441 ERCC3 A/G 216 292 92 600 0.397 201 300 98 599 0.414 42 58 17 0.393 159 242 81 0.419 86 116 45 0.417 58 93 27 0.413 
rs4150474 ERCC3 T/G 325 242 33 600 0.257 353 220 30 603 0.232 65 49 3 0.235 288 171 27 0.231 149 87 14 0.230 104 65 9 0.233 
rs4234259 MLH1 A/G 165 278 154 597 0.491 150 309 141 600 0.493 31 63 23 0.466 127 246 110 0.482 65 124 59 0.488 47 92 38 0.475 
rs4253160 ERCC6 A/T 181 290 131 602 0.458 192 293 114 599 0.435 37 54 25 0.448 155 239 89 0.432 87 107 54 0.433 54 94 29 0.429 
rs4968451 BRIP1 A/C 407 176 17 600 0.175 422 166 13 601 0.160 82 33 2 0.158 340 133 11 0.160 172 71 5 0.163 121 53 4 0.171 
rs4986764 BRIP1 C/T 224 270 107 601 0.403 232 297 69 598 0.364 35 67 13 0.404 197 230 56 0.354 93 130 25 0.363 76 74 27 0.362 
rs4987876 ATM G/T 497 94 9 600 0.093 511 79 11 601 0.084 96 20 1 0.094 415 59 10 0.082 217 26 7 0.080 151 23 2 0.077 
rs569143 MRE11A C/G 158 297 146 601 0.490 158 308 132 598 0.478 29 59 28 0.496 130 249 103 0.472 66 127 54 0.476 51 89 37 0.460 
rs5744934 POLE A/G 415 168 16 599 0.167 417 159 25 601 0.174 84 29 3 0.151 333 130 22 0.179 174 63 13 0.178 115 54 8 0.198 
rs601341 MRE11A G/A 179 307 113 599 0.445 203 299 97 599 0.412 35 63 19 0.432 168 236 78 0.407 84 122 40 0.411 61 88 29 0.410 
rs6413436 RAD52 T/C 274 263 64 601 0.325 257 261 84 602 0.356 49 50 18 0.368 208 211 66 0.354 108 106 35 0.353 68 85 25 0.379 
rs664143 ATM C/T 226 288 89 603 0.386 248 280 73 601 0.354 52 50 15 0.342 196 230 58 0.357 105 116 28 0.345 69 83 25 0.376 
rs7182283 NEIL1 G/T 171 280 144 595 0.477 169 309 118 596 0.457 29 65 22 0.470 140 244 96 0.454 70 126 49 0.457 55 86 36 0.446 
rs735943 EXO1 C/T 174 279 149 602 0.479 173 302 124 599 0.459 35 58 24 0.453 138 244 100 0.461 75 130 44 0.438 44 87 44 0.500 
rs7797466 PMS2 G/A 439 142 20 601 0.151 419 170 13 602 0.163 87 26 4 0.145 332 144 9 0.167 175 69 5 0.159 123 52 3 0.163 
rs799917 BRCA1 C/T 250 281 69 600 0.349 234 297 69 600 0.363 41 63 13 0.380 193 234 56 0.358 100 118 31 0.361 73 88 15 0.335 
rs8305 POLI A/G 329 236 38 603 0.259 308 245 50 603 0.286 66 43 8 0.252 242 202 42 0.294 130 99 21 0.282 85 77 16 0.306 
rs861528 XRCC3 G/A 350 205 33 588 0.230 279 219 30 528 0.264 61 43 3 0.229 218 176 27 0.273 124 81 12 0.242 66 73 13 0.326 
rs861531 XRCC3 G/T 230 277 88 595 0.381 210 298 89 597 0.399 43 56 17 0.388 167 242 72 0.401 97 116 33 0.370 50 96 31 0.446 
rs861539 XRCC3 C/T 238 277 88 603 0.376 227 293 83 603 0.381 43 58 16 0.385 184 235 67 0.380 106 115 29 0.346 57 91 30 0.424 
rs9350 EXO1 C/T 430 150 19 599 0.157 439 143 14 596 0.143 87 25 4 0.142 352 118 10 0.144 184 58 4 0.134 127 45 4 0.151 
rs963248 XRCC4 A/G 422 165 15 602 0.162 419 168 16 603 0.166 83 33 1 0.150 336 135 15 0.170 164 77 9 0.190 127 48 3 0.152 
rs9876116 MLH1 A/G 173 279 149 601 0.480 161 308 131 600 0.475 29 64 24 0.479 137 244 102 0.464 70 120 58 0.476 52 93 32 0.444 
rs9894946 TP53 G/A 409 165 18 592 0.170 452 138 6 596 0.126 92 23 ― 0.100 360 115 6 0.132 188 56 4 0.129 123 51 2 0.156 
                             
 
n, number of individuals; A/a, major/minor alleles; MAF, minor allele frequency. 
N, number of individuals successfully genotyped. 
Supplementary Table 3: Significant SNPs in DNA repair genes associated with gastric cancer risk. 
Univariate analysis Multivariate analysis*  
Codominant Dominant Recessive Log-additive Codominant Dominant Recessive Log-Additive 
Gen db SNP ID OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)   P value OR (95% CI)   P value 
TP53 rs1042522 0.82 (0.52–1.31)  0.471 0.68 (0.54–0.85)  0.001 0.97 (0.61-1.53) 0.912 0.78 (0.64–0.93)  0.007 0.88 (0.55–1.42)  0.609 0.67 (0.53–0.85)  0.001 1.05 (0.66–1.67)  0.832 0.78 (0.65–0.94)  0.009 
RAD52 rs11226 1.49 (1.06–2.10)  0.024 1.24 (0.96–1.59)  0.092 1.37 (1.02–1.86)  0.039 1.21 (1.03–1.43)  0.023 1.51 (1.06–2.13)   0.017 1.23 (0.95–1.59) 0.111 1.40 (1.03–1.91)   0.032 1.21 (1.02–1.44)  0.025 
ERCC5 rs17655 0.67 (0.42–1.05)  0.085 0.80 (0.64–1.01)  0.058 0.72 (0.46–1.12)  0.144 0.82 (0.69–0.99)  0.035 0.63 (0.39–1.01)  0.052 0.77 (0.61–0.97)  0.025 0.69 (0.43–1.09)  0.109 0.79 (0.66–0.96)  0.015 
POLG rs176641 1.25 (0.86–1.79)  0.265 1.32 (1.05–1.67)  0.016 1.06 (0.76–1.49)  0.721 1.18 (1.00–1.39)  0.055 1.24 (0.86–1.80)  0.108 1.29 (1.02–1.63)  0.036 1.08 (0.76–1.53)  0.659 1.16 (0.98–1.38)  0.082 
BRCA2 rs1801406 0.58 (0.36–0.92)  0.028 0.99 (0.79–1.24)  0.913 0.56 (0.36–0.88)  0.011 0.90 (0.75–1.08)  0.252 0.61 (0.38–0.97)  0.038 0.98 (0.77–1.23)  0.837 0.60 (0.38–0.95)  0.027 0.90 (0.75–1.09)  0.277 
LIG3 rs2074522 6.67 (1.50–29.67) 0.009 1.21 (0.89-1.64)  0.227 6.59 (1.48–29.28) 0.002 1.30 (0.98 –1.71) 0.064 7.15 (1.60–31.97) 0.007 1.22 (0.89–1.67)  0.217 7.05 (1.58–31.53) 0.001 1.32 (0.99–1.75)  0.055 
XPC rs2228000 0.78 (0.52–1.17)  0.257 0.73 (0.58–0.92)  0.006 0.91 (0.62–1.34)  0.621 0.82 (0.68–0.97)  0.021 0.82 (0.55–1.24)  0.829    0.73 (0.58–0.92)  0.008 0.96 (0.65–1.43)  0.854 0.83 (0.69–0.99)  0.035 
ERCC4 rs2238463 0.71 (0.50–1.02)  0.070 0.75 (0.60–0.95)  0.016 0.83 (0.60–1.16)  0.280 0.82 (0.70–0.97)  0.023 0.71 (0.49–1.03)  0.059 0.75 (0.59–0.95)  0.019 0.83 (0.59–1.17)  0.325 0.82 (0.69–0.98)  0.025 
MGMT rs2308321 0.18 (0.04–0.84)  0.028 1.00 (0.73–1.35)  0.984 0.18 (0.04–0.83)  0.009 0.91 (0.69–1.20)  0.517 0.20 (0.04–0.93)  0.039 1.03 (0.75–1.41)  0.858 0.20 (0.04–0.91)  0.015 0.94 (0.71–1.25)  0.665 
MSH3 rs26779 0.77 (0.55–1.10)  0.159 0.78 (0.62–0.98)  0.036 0.90 (0.62–0.98)  0.496 0.86 (0.73–1.01)  0.068 0.80 (0.56–1.14)  0.242 0.81 (0.64–1.04)  0.093 0.90 (0.65–1.24)  0.509 0.88 (0.74–1.04)  0.127 
ERCC4 rs3136038 0.70 (0.48–1.01)  0.073 0.78 (0.62–0.98)  0.033 0.79 (0.56–1.12)  0.186 0.83 (0.70–0.98)  0.027  0.68 (0.46–0.99)  0.049 0.77 (0.61–0.98)  0.032 0.76 (0.53–1.09)  0.138 0.81 (0.68–0.97)  0.021 
BRIP1 rs4986764 0.62 (0.43–0.88)  0.009 0.94 (0.74–1.18)  0.586 0.60 (0.43–0.83)  0.002  0.85 (0.72–0.99)  0.049 0.62  (0.43–0.89)  0.007   0.94 (0.74–1.20)  0.633 0.59 (0.42–0.83)  0.002 0.85 (0.72–1.00)  0.055 
XRCC3 rs861528 1.14 (0.67–1.91)  0.690 1.31 (1.04–1.36)  0.024 1.01 (0.61–1.69)  0.959 1.20 (0.99–1.46)  0.061 1.20 (0.71–2.03)  0.432   1.35 (1.06–1.72)  0.015   1.05 (0.62–1.76)  0.862    1.23 (1.01–1.51)  0.038 
TP53 rs9894946 0.30 (0.11–0.76)  0.011 0.71 (0.55–0.92)  0.009 0.32 (0.13–0.82)  0.010 0.70 (0.56–0.88)  0.002 0.21 (0.07–0.64)  0.001 0.69 (0.53–0.90)  0.006 0.23 (0.08–0.68)  0.002 0.67 (0.53–0.85)  0.001 
OR, odds ratio; 95% CI, 95% confidence interval.  
ORs and 95% CI in the multivariate analysis were adjusted for age, gender, H. pylori infection, smoking habit, and family history of GC. 
P values < 0.05 are highlighted in bold. 
Supplementary Table 4: Association of DNA repair gene polymorphisms with risk of Helicobacter pylori infection in healthy controls. 
 Helicobacter pylori infection CagA status VacA status 
  Log-additive genetic model Log-additive genetic model Log-additive genetic model 
   95% CI    95% CI    95% CI   
db SNP ID Gen ORa Lower Upper P-value FDRb ORa Lower Upper P-value FDRb ORa Lower Upper P-value FDRb 
rs10079641 MSH3 0.72 0.49 1.05 0.092 0.583 0.88 0.52 1.50 0.651 0.964 0.65 0.39 1.07 0.025 0.672 
rs1042522 TP53 1.16 0.89 1.51 0.277 0.869 0.84 0.58 1.20 0.339 0.924 0.93 0.66 1.33 0.708 0.968 
rs1047768 ERCC5 1.13 0.90 1.42 0.301 0.869 0.95 0.70 1.29 0.741 0.964 0.81 0.60 1.09 0.170 0.708 
rs1047840 EXO1 0.95 0.75 1.20 0.654 0.989 0.70 0.51 0.97 0.033 0.924 0.99 0.73 1.36 0.963 0.973 
rs1048771 RAD54L 1.09 0.75 1.59 0.657 0.989 0.66 0.40 1.08 0.102 0.924 0.78 0.48 1.28 0.282 0.794 
rs1051677 XRCC5 1.15 0.76 1.74 0.517 0.989 0.71 0.41 1.21 0.208 0.924 0.66 0.39 1.11 0.120 0.672 
rs1051685 XRCC5 1.18 0.81 1.73 0.384 0.869 1.08 0.65 1.78 0.766 0.964 0.92 0.57 1.47 0.719 0.970 
rs1052133 OGG1 1.16 0.87 1.54 0.321 0.869 0.88 0.61 1.27 0.485 0.940 0.81 0.57 1.15 0.239 0.739 
rs1059262 ALKBH2 0.86 0.64 1.15 0.301 0.869 0.89 0.59 1.35 0.587 0.940 1.18 0.90 1.54 0.236 0.739 
rs1060915 BRCA1 1.05 0.82 1.35 0.706 0.989 1.17 0.83 1.64 0.371 0.924 1.02 0.74 1.41 0.903 0.973 
rs11226 RAD52 1.02 0.80 1.29 0.881 0.989 1 0.72 1.39 0.983 0.990 0.91 0.66 1.25 0.553 0.910 
rs1130409 APEX1 1 0.79 1.26 0.995 0.995 1.18 0.86 1.62 0.318 0.924 1.16 0.85 1.57 0.356 0.854 
rs1136410 PARP1 1.20 0.84 1.73 0.316 0.869 1.15 0.71 1.86 0.580 0.940 1.09 0.68 1.72 0.287 0.794 
rs13180316 XRCC4 0.94 0.72 1.21 0.615 0.989 1.34 0.92 1.96 0.118 0.924 0.8 0.56 1.13 0.198 0.708 
rs13181 ERCC2 0.93 0.74 1.18 0.570 0.989 0.99 0.71 1.38 0.943 0.964 0.75 0.54 1.03 0.074 0.672 
rs1346044 WRN 1.29 0.98 1.70 0.072 0.583 0.76 0.53 1.08 0.131 0.924 0.87 0.62 1.23 0.438 0.885 
rs144848 BRCA2 1.03 0.79 1.34 0.840 0.989 0.85 0.59 1.22 0.380 0.924 0.74 0.52 1.05 0.095 0.672 
rs1478485 XRCC4 1.12 0.89 1.42 0.330 0.869 0.98 0.71 1.35 0.895 0.964 1.01 0.73 1.38 0.973 0.973 
rs1540354 MLH1 0.97 0.69 1.36 0.856 0.989 1.54 0.91 2.60 0.097 0.924 0.82 0.52 1.30 0.402 0.885 
rs1614984 TP53 1.20 0.95 1.53 0.130 0.666 1.09 0.79 1.51 0.592 0.940 1.19 0.87 1.62 0.280 0.794 
rs1618536 ERCC2 1.21 0.96 1.51 0.101 0.583 0.90 0.67 1.23 0.522 0.940 0.99 0.73 1.33 0.944 0.973 
rs1650697 MSH3 1.03 0.79 1.34 0.831 0.989 0.95 0.66 1.35 0.762 0.964 1.06 0.75 1.50 0.747 0.973 
rs174538 FEN1 0.98 0.76 1.26 0.865 0.989 0.95 0.67 1.35 0.771 0.964 1.32 0.93 1.87 0.116 0.672 
rs175080 MLH3 0.98 0.78 1.23 0.828 0.989 0.88 0.64 1.2 0.423 0.924 1.02 0.76 1.39 0.884 0.973 
rs1760944 APEX1 0.88 0.68 1.13 0.315 0.869 0.96 0.68 1.34 0.804 0.964 0.78 0.56 1.08 0.131 0.672 
rs17655 ERCC5 1.13 0.87 1.46 0.360 0.869 1.23 0.86 1.74 0.253 0.924 0.82 0.59 1.14 0.239 0.739 
rs176641 POLG 1.06 0.83 1.35 0.634 0.989 0.86 0.62 1.20 0.382 0.924 1.14 0.83 1.57 0.421 0.885 
rs1776148 EXO1 1.05 0.83 1.32 0.713 0.989 0.90 0.65 1.24 0.512 0.940 0.94 0.69 1.28 0.693 0.968 
rs1799793 ERCC2 0.94 0.73 1.20 0.603 0.989 1.01 0.72 1.42 0.946 0.964 0.85 0.62 1.18 0.328 0.805 
rs1799794 XRCC3 0.95 0.73 1.24 0.725 0.989 1.16 0.80 1.68 0.426 0.924 1.12 0.78 1.59 0.544 0.910 
rs1799796 XRCC3 0.80 0.61 1.05 0.108 0.583 1.21 0.81 1.81 0.352 0.924 1.10 0.75 1.61 0.635 0.939 
rs1799801 ERCC4 0.99 0.77 1.27 0.933 0.989 0.94 0.68 1.31 0.723 0.964 1.28 0.92 1.78 0.137 0.672 
rs1799955 BRCA2 0.73 0.55 0.97 0.030 0.539 0.98 0.65 1.46 0.907 0.964 1.23 0.82 1.83 0.316 0.798 
rs1799966 BRCA1 1.05 0.82 1.34 0.712 0.989 1.12 0.80 1.56 0.526 0.940 0.99 0.71 1.36 0.932 0.973 
rs1799977 MLH1 0.96 0.75 1.22 0.725 0.989 0.79 0.57 1.09 0.158 0.924 0.82 0.60 1.12 0.203 0.708 
rs1800067 ERCC4 1.31 0.91 1.91 0.146 0.685 0.89 0.56 1.41 0.613 0.945 1.37 0.85 2.21 0.189 0.708 
rs1800389 WRN 1.01 0.78 1.30 0.947 0.989 0.96 0.68 1.35 0.808 0.964 1.17 0.83 1.64 0.370 0.867 
rs1800734 MLH1 0.92 0.70 1.19 0.522 0.989 1.21 0.83 1.76 0.319 0.924 1.21 0.85 1.74 0.289 0.794 
rs1800935 MSH6 1.13 0.87 1.48 0.348 0.869 0.92 0.65 1.31 0.655 0.964 0.75 0.53 1.05 0.099 0.672 
rs1800975 XPA 1.06 0.83 1.36 0.618 0.989 1.10 0.79 1.54 0.579 0.940 0.87 0.63 1.19 0.386 0.885 
rs1801406 BRCA2 0.77 0.60 1 0.048 0.583 0.97 0.68 1.39 0.874 0.964 1.04 0.74 1.47 0.830 0.973 
rs1801516 ATM 1 0.71 1.41 0.985 0.994 1.62 0.98 2.67 0.153 0.924 1.77 1.09 2.87 0.017 0.614 
rs1802904 ATR 1.25 0.86 1.80 0.235 0.869 1.24 0.76 2.02 0.383 0.924 0.99 0.63 1.56 0.971 0.973 
rs1805386 LIG4 1.30 0.95 1.80 0.102 0.583 1.18 0.77 1.79 0.441 0.924 0.96 0.76 1.22 0.751 0.973 
rs1805388 LIG4 0.99 0.70 1.39 0.937 0.989 1.26 0.77 2.05 0.357 0.924 0.84 0.54 1.32 0.451 0.885 
rs1805794 NBS1 1.11 0.87 1.43 0.394 0.869 1.02 0.73 1.44 0.892 0.964 1.01 0.73 1.40 0.945 0.973 
rs1981928 MSH2 0.87 0.67 1.13 0.295 0.869 0.87 0.62 1.24 0.444 0.924 0.77 0.55 1.08 0.128 0.672 
rs2020911 MSH6 0.92 0.72 1.16 0.482 0.989 0.83 0.6 1.15 0.265 0.924 0.94 0.68 1.28 0.678 0.963 
rs2040639 XRCC2 1.06 0.84 1.33 0.614 0.989 0.94 0.69 1.28 0.696 0.964 0.97 0.72 1.31 0.845 0.973 
rs2048718 BRIP1 1.16 0.92 1.48 0.213 0.869 0.69 0.49 0.95 0.023 0.924 0.73 0.53 1.01 0.054 0.672 
rs20580 LIG1 1.34 1.07 1.69 0.011 0.420 1.01 0.74 1.39 0.940 0.964 1.26 0.92 1.71 0.147 0.687 
rs2074522 LIG3 1.10 0.71 1.72 0.752 0.989 1.30 0.70 2.40 0.825 0.964 1.22 0.68 2.19 0.494 0.909 
rs2075685 XRCC4 1.22 0.97 1.55 0.090 0.583 0.92 0.67 1.26 0.584 0.940 1.13 0.83 1.54 0.426 0.885 
rs207906 XRCC5 1.03 0.73 1.45 0.882 0.989 1.27 0.78 2.08 0.327 0.924 1.06 0.67 1.67 0.799 0.973 
rs2228000 XPC 0.78 0.60 1 0.048 0.583 1.07 0.75 1.51 0.721 0.964 0.91 0.65 1.27 0.583 0.925 
rs2228001 XPC 1.03 0.81 1.30 0.823 0.989 1.22 0.88 1.69 0.226 0.924 1.03 0.76 1.41 0.837 0.973 
rs2228006 PMS2 1.04 0.76 1.42 0.802 0.989 1.25 0.81 1.94 0.307 0.924 1.06 0.70 1.59 0.787 0.973 
rs2238463 ERCC4 1.05 0.82 1.34 0.696 0.989 1.02 0.73 1.42 0.912 0.964 1.36 0.99 1.89 0.059 0.672 
rs2252775 RAD50 0.88 0.66 1.19 0.414 0.885 0.93 0.62 1.39 0.733 0.964 1.14 0.77 1.70 0.505 0.909 
rs2272615 POLB 1.03 0.73 1.47 0.851 0.989 1.23 0.76 2.01 0.395 0.924 1.27 0.79 2.04 0.318 0.798 
rs2286940 MLH1 1.01 0.81 1.26 0.940 0.989 0.83 0.61 1.13 0.233 0.924 0.89 0.66 1.19 0.436 0.885 
rs2303428 MSH2 0.96 0.66 1.40 0.826 0.989 0.72 0.44 1.18 0.199 0.924 0.88 0.54 1.45 0.626 0.939 
rs2308321 MGMT 0.89 0.66 1.21 0.463 0.885 1.30 0.72 2.35 0.369 0.924 0.84 0.50 1.43 0.530 0.909 
rs2345060 PMS2 1.22 0.93 1.6 0.141 0.685 0.89 0.62 1.28 0.535 0.940 1.11 0.78 1.58 0.565 0.910 
rs2348244 MSH6 0.91 0.65 1.27 0.584 0.989 1.16 0.72 1.86 0.541 0.940 1.54 0.95 2.48 0.069 0.672 
rs238406 ERCC2 1.21 0.97 1.52 0.091 0.583 0.87 0.64 1.17 0.355 0.924 0.94 0.70 1.27 0.704 0.968 
rs2434470 ALKBH3 0.94 0.72 1.23 0.645 0.989 1.40 0.95 2.06 0.086 0.924 0.95 0.67 1.36 0.782 0.973 
rs2440 XRCC5 0.95 0.76 1.21 0.695 0.989 1.03 0.75 1.42 0.837 0.964 1.08 0.80 1.47 0.607 0.939 
rs25487 XRCC1 1.11 0.88 1.39 0.394 0.869 1.13 0.82 1.55 0.454 0.924 0.74 0.55 1.01 0.054 0.672 
rs26279 MSH3 1.02 0.80 1.30 0.875 0.989 1.20 0.86 1.67 0.292 0.924 1.01 0.74 1.39 0.933 0.973 
rs26779 MSH3 0.88 0.69 1.12 0.285 0.869 0.93 0.67 1.30 0.676 0.964 0.98 0.71 1.34 0.876 0.973 
rs293794 OGG1 0.87 0.65 1.18 0.388 0.869 1.22 0.79 1.87 0.363 0.924 1.01 0.68 1.51 0.967 0.973 
rs3136038 ERCC4 1.07 0.84 1.36 0.604 0.989 1.04 0.74 1.44 0.835 0.964 1.37 0.99 1.90 0.056 0.672 
rs3136228 MSH6 1.09 0.85 1.39 0.515 0.989 0.96 0.69 1.35 0.824 0.964 0.74 0.53 1.02 0.067 0.672 
rs3212948 ERCC1 0.80 0.63 1.01 0.061 0.583 0.91 0.66 1.25 0.555 0.940 0.85 0.62 1.16 0.294 0.794 
rs3212961 ERCC1 0.80 0.56 1.15 0.232 0.869 1.15 0.67 1.96 0.946 0.964 1.33 0.78 2.26 0.518 0.909 
rs3212986 ERCC1 0.89 0.69 1.16 0.391 0.869 0.87 0.61 1.26 0.472 0.940 0.76 0.54 1.08 0.133 0.672 
rs3213245 XRCC1 1 0.79 1.27 0.969 0.989 0.94 0.68 1.28 0.685 0.964 1.21 0.89 1.64 0.226 0.739 
rs3218536 XRCC2 1.01 0.68 1.50 0.961 0.989 1.18 0.67 2.07 0.843 0.964 1.36 0.78 2.36 0.610 0.939 
rs3219489 MUTYH 0.99 0.76 1.29 0.945 0.989 0.95 0.66 1.37 0.801 0.964 1.03 0.73 1.47 0.863 0.973 
rs3626 PCNA 0.91 0.65 1.28 0.590 0.989 1.61 0.95 2.71 0.150 0.924 1.37 0.85 2.22 0.193 0.708 
rs3730668 POLI 1.08 0.85 1.38 0.524 0.989 1.42 1 2.01 0.047 0.924 1.14 0.82 1.59 0.446 0.885 
rs3793784 ERCC6 1.22 0.96 1.53 0.097 0.583 0.85 0.62 1.17 0.330 0.924 0.99 0.73 1.34 0.934 0.973 
rs4150416 ERCC3 1.26 0.98 1.62 0.075 0.583 1.08 0.76 1.52 0.670 0.964 0.79 0.57 1.09 0.153 0.687 
rs4150441 ERCC3 0.98 0.77 1.25 0.885 0.989 1.02 0.75 1.40 0.884 0.964 1.14 0.84 1.55 0.406 0.885 
rs4150474 ERCC3 1.18 0.9 1.54 0.236 0.869 1.02 0.71 1.47 0.899 0.964 0.79 0.56 1.12 0.194 0.708 
rs4234259 MLH1 1 0.80 1.25 0.970 0.989 0.84 0.62 1.14 0.269 0.924 0.91 0.68 1.21 0.506 0.909 
rs4253160 ERCC6 1.23 0.98 1.55 0.077 0.583 0.87 0.63 1.19 0.369 0.924 1.02 0.75 1.38 0.902 0.973 
rs4968451 BRIP1 1.36 0.99 1.87 0.052 0.583 0.77 0.52 1.14 0.194 0.924 0.92 0.62 1.35 0.658 0.961 
rs4986764 BRIP1 1.01 0.81 1.27 0.920 0.989 1.16 0.84 1.59 0.365 0.924 0.97 0.71 1.31 0.826 0.973 
rs4987876 ATM 1.52 1.01 2.28 0.041 0.583 0.83 0.51 1.33 0.436 0.924 0.96 0.60 1.54 0.864 0.973 
rs569143 MRE11A 0.98 0.78 1.23 0.835 0.989 1.09 0.79 1.49 0.601 0.941 0.91 0.67 1.23 0.523 0.909 
rs5744934 POLE 1.17 0.85 1.61 0.327 0.869 1 0.66 1.52 0.990 0.990 0.94 0.63 1.41 0.765 0.973 
rs601341 MRE11A 0.89 0.70 1.13 0.326 0.869 0.98 0.71 1.36 0.905 0.964 1.12 0.81 1.53 0.491 0.909 
rs6413436 RAD52 1.08 0.84 1.38 0.543 0.989 0.86 0.61 1.2 0.363 0.924 0.95 0.69 1.32 0.780 0.973 
rs664143 ATM 1 0.78 1.26 0.971 0.989 0.96 0.69 1.34 0.825 0.964 0.95 0.69 1.31 0.750 0.973 
rs7182283 NEIL1 0.89 0.71 1.12 0.313 0.869 0.76 0.56 1.04 0.090 0.924 0.85 0.63 1.16 0.308 0.798 
rs735943 EXO1 1.11 0.89 1.39 0.358 0.869 0.89 0.65 1.20 0.429 0.924 1.29 0.96 1.74 0.085 0.672 
rs7797466 PMS2 0.78 0.57 1.06 0.107 0.583 1.14 0.72 1.81 0.566 0.940 1.04 0.68 1.61 0.844 0.973 
rs799917 BRCA1 1.04 0.81 1.33 0.782 0.989 1.07 0.76 1.49 0.708 0.964 0.93 0.68 1.29 0.676 0.963 
rs8305 POLI 1.03 0.79 1.35 0.821 0.989 0.87 0.61 1.25 0.453 0.924 1.31 0.92 1.89 0.134 0.672 
rs861528 XRCC3 1.12 0.85 1.48 0.418 0.885 0.90 0.62 1.30 0.580 0.940 0.88 0.62 1.26 0.491 0.909 
rs861531 XRCC3 1.15 0.91 1.47 0.240 0.869 0.81 0.59 1.11 0.181 0.924 0.81 0.60 1.10 0.186 0.708 
rs861539 XRCC3 1.12 0.88 1.41 0.363 0.869 0.79 0.57 1.08 0.135 0.924 0.83 0.61 1.12 0.217 0.731 
rs9350 EXO1 0.83 0.61 1.13 0.250 0.869 0.73 0.48 1.12 0.155 0.924 0.72 0.48 1.10 0.131 0.672 
rs963248 XRCC4 0.96 0.70 1.31 0.799 0.989 0.97 0.63 1.51 0.906 0.964 0.88 0.58 1.34 0.557 0.910 
rs9876116 MLH1 0.99 0.79 1.24 0.954 0.989 0.80 0.59 1.08 0.139 0.924 0.93 0.70 1.25 0.629 0.939 
rs9894946 TP53 0.96 0.71 1.31 0.807 0.989 0.83 0.55 1.25 0.379 0.924 1.02 0.68 1.54 0.906 0.973 
OR, odds ratio; CI, confidence interval. 
aORs adjusted by gender, age, smoking habit, and family history of GC. 
bQFDR-values obtained after applying the False Discovery Rate (FDR) test.  
P-values <0.05 are highlighted in bold. 
 Supplementary Table 5: Significant SNPs associated with gastric cancer risk. Association analysis stratified by anatomical location of the tumor. 
Univariate analysis Multivariate analysis*  
CARDIA GC 
Codominant Dominant Recessive Log-additive Codominant Dominant Recessive Log-Additive 
Gen db SNP ID OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)   P value OR (95% CI)   P value 
RAD52 rs11226 1.81 (0.99-3.30)  0.112 1.58 (0.99-2.58)  0.059 1.40 (0.84-2.34)  0.202 1.35 (1.01-1.82)  0.042 1.65 (0.88-3.09)  0.143 1.59 (0.99-2.57)  0.049 1.25 (0.73-2.14)  0.416 1.31 (0.97-1.77)  0.081 
ERCC4 rs1799801 0.74 (0.37-1.47)  0.508 0.57 (0.38-0.85)  0.005 0.95 (0.48-1.87)  0.855 0.70 (0.51-0.97)  0.027 0.66 (0.31-1.42)  0.289 0.58 (0.38-0.88)  0.010 0.84 (0.40-1.77)  0.640 0.69 (0.49-0.97)  0.028 
MLH1 rs1799977 1.64 (0.89-3.01)  0.128 1.52 (1.01-2.30)  0.042 1.32 (0.76-2.31)  0.339 1.32 (1.00-1.76)  0.055 1.65 (0.87-3.11)  0.122 1.46 (0.95-2.24)  0.079 1.38 (0.77-2.47)  0.291 1.31 (0.97-1.77)  0.075 
LIG4 rs1805388 1.95 (0.52-7.26)  0.399 1.60 (1.03-2.50)  0.041 1.72 (0.46-6.35)  0.440 1.52 (1.03-2.24)  0.041 2.16 (0.56-8.29)  0.261 1.58 (0.99-2.51)  0.051   1.91 (0.50-7.26)  0.368  1.52 (1.01-2.28)  0.048 
BRIP1 rs2048718 0.37 (0.17-0.78)  0.007 0.72 (0.47-1.10)  0.130 0.40 (0.20-0.82)  0.005 0.68 (0.50-0.93)  0.014 0.43 (0.20-0.93)  0.031 0.71 (0.46-1.11)  0.135   0.49 (0.24-0.93)  0.034 0.71 (0.51-0.96)  0.033 
ERCC4 rs2238463 0.61 (0.33-1.13)  0.145 0.54 (0.37-0.81)  0.002 0.85 (0.47-1.52)  0.575 0.69 (0.51-0.95)  0.017 0.57 (0.29-1.10)  0.096 0.54 (0.35-0.81)  0.003 0.79 (0.42-1.49)  0.462 0.67 (0.49-0.92)  0.012 
ERCC4 rs3136038 0.66 (0.35-1.25)  0.229 0.59 (0.39-0.87)  0.008 0.88 (0.48-1.61)  0.678 0.72 (0.53-0.98)  0.032 0.60 (0.30-1.19)  0.143 0.57 (0.38-0.87)  0.009    0.80 (0.42-1.53)  0.486  0.69 (0.50-0.96)  0.023 
POL1 rs3730668 1.53 (0.88-2.64)  0.152 0.98 (0.64-1.51)  0.920 1.74 (1.08-2.80)  0.025 1.20 (0.90-1.60)  0.222 1.49 (0.84-2.63)  0.175 0.98 (0.63-1.54)  0.938  1.68 (1.02-2.74)  0.046 1.19 (0.88-1.60)  0.268 
TP53 rs9894946 NA 0.56 (0.34-0.91)  0.015 NA 0.54 (0.34-0.86)  0.020 NA 0.51 (0.30-0.86)  0.011 NA 0.50 (0.30-0.81)  0.002 
Univariate analysis Multivariate analysis* 
NON-CARDIA GC 
Codominant Dominant Recessive Log-additive Codominant Dominant Recessive Log-Additive 
Gen db SNP ID OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)   P value OR (95% CI)   P value 
TP53 rs1042522 0.91 (0.56-1.47)  0.715   0.67 (0.52-0.85)  0.001 1.09 (0.68-1.74)  0.724 0.78 (0.64-0.95)  0.013 1.01 (0.62-1.66)  0.938 0.67 (0.52-0.87)  0.001    1.22 (0.76-1.97)  0.416 0.80 (0.65-0.98)  0.028 
POLG rs176641 1.27 (0.86-1.88)  0.232 1.42 (1.11-1.82)  0.004 1.03 (0.72-1.48)  0.864 1.21 (1.02-1.45)  0.032 1.27 (0.85-1.89)  0.245 1.40 (1.09-1.81)  0.008 1.04 (0.72-1.50)  0.848 1.21 (1.00-1.46)  0.054  
BRCA2 rs1801406 0.56 (0.34-0.92)  0.021 0.96 (0.75-1.22)  0.734 0.55 (0.33-0.89)  0.012  0.88 (0.72-1.07)  0.191 0.58 (0.35-0.97)  0.039 0.96 (0.75-1.23)  0.761 0.57 (0.34-0.94)  0.023 0.89 (0.73-1.08)  0.235 
LIG3 rs2074522 7.7 (1.73-34.90)  0.002 1.32 (0.961.82)  0.083 7.57 (1.69-34.97) 0.001 1.42 (1.06-1.89)  0.017 8.20 (1.81-37.14) 0.006   1.37 (0.99-1.90)  0.057    7.94 (1.76-35.91) 0.001 1.46 (1.09-1.96)  0.010 
XPC rs2228000 0.78 (0.51-1.20)  0.281 0.72 (0.57-0.91)  0.007 0.92 (0.61-1.38)  0.681 0.81 (0.67-0.97)  0.024 0.81 (0.53-1.26)  0.354 0.70 (0.55-0.90)  0.004    0.98 (0.64-1.48)  0.907 0.81 (0.67-0.98)  0.026 
MSH6 rs2348244 0.32 (0.09-1.14)  0.101 0.73 (0.55-0.98)  0.032 0.33 (0.09-1.21)  0.068 0.72 (0.55-0.94)  0.016 0.33 (0.09-1.20)  0.092 0.74 (0.55-0.99) 0.044    0.35 (0.10-1.27)  0.082 0.73 (0.56-0.96)  0.023 
MSH3 rs26779 0.78 (0.55-1.13)  0.198 0.74 (0.58-0.94)  0.015    0.94 (0.67-1.31)  0.714 0.85 (0.71-1.01)  0.059 0.80 (0.55-1.17)  0.259 0.76 (0.59-0.99) 0.039   0.94 (0.67-1.33)  0.745 0.86 (0.72-1.03)  0.106 
ERCC3 rs4150416 0.77 (0.50-1.18)  0.232 0.76 (0.60-0.97)  0.028 0.87 (0.57-1.32)  0.506 0.83 (0.69-0.99)  0.047 0.72 (0.46-1.13)  0.157 0.73 (0.57-0.94)  0.013 0.84 (0.55-1.29)  0.429 0.80 (0.66-0.97)  0.024 
BRIP1 rs4986764 0.60 (0.41-0.87)  0.007 0.86 (0.67-1.10)  0.238 0.61 (0.43-0.86)  0.004 0.82 (0.69-0.97)  0.021 0.58 (0.39-0.86)  0.007 0.87 (0.67-1.11) 0.249    0.59 (0.41-0.85)  0.003   0.81 (0.68- 0.97)  0.022 
XRCC3 rs861528 1.31 (0.77-2.25)  0.332 1.37 (1.06-1.76)  0.014 1.15 (0.68-1.95)  0.596 1.26 (1.03-1.55)  0.027 1.41 (0.82-2.44)  0.218 1.45 (1.11-1.88)  0.010  1.21 (0.71-2.06)  0.494 1.31 (1.06-1.62)  0.011 
TP53 rs9894946 0.38 (0.15-0.96)  0.038 0.75 (0.57-0.98)  0.036  0.40 (0.16-1.02)  0.060  0.74 (0.58-0.94)  0.014 0.27 (0.09-0.82)  0.021 0.74 (0.56-0.98)  0.033 0.29 (0.10-0.87)  0.014 0.72 (0.56-0.93)  0.009 
OR, odds ratio; 95% CI, 95% confidence interval; NA, not applied. 
ORs and 95% CI in the multivariate analysis were adjusted for age, gender, H. pylori infection, smoking habit, and family history of GC. 
P values < 0.05 are highlighted in bold. 
Supplementary Table 6: Significant SNPs associated with gastric cancer risk. Association analysis stratified by histological tumor type. 
Univariate analysis Multivariate analysis*  
INTESTINAL GC 
Codominant Dominant Recessive Log-additive Codominant Dominant Recessive Log-Additive 
Gen db SNP ID OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)   P value OR (95% CI)   P value 
TP53 rs1042522 1.05 (0.59-1.85)  0.884  0.73 (0.54-0.98)  0.038 0.82 (0.47-1.43)  0.466 0.85 (0.66-1.08)  0.170 1.08 (0.60-1.95)  0.793 0.72 (0.53-0.98)  0.037  0.89 (0.71-2.26)  0.431 0.84 (0.66-1.08)  0.180 
ERCC5 rs17655 0.74 (0.42-1.32)  0.332 0.65 (0.48-0.88)  0.005 0.88 (0.50-1.55)  0.657  0.75 (0.59-0.95)  0.017 0.62 (0.33-1.16)  0.136 0.60 (0.43-0.82)  0.001 0.75 (0.40-1.39)  0.351 0.69 (0.53-0.89)  0.003 
POLG rs176641 1.23 (0.76-2.00)  0.448    1.41 (1.04-1.91)  0.027 1.00 (0.64-1.57)  0.996 1.19 (0.96-1.49)  0.110 1.25 (0.75-2.06)  0.385    1.40 (1.02-1.93)  0.035  1.02 (0.64-1.62)  0.936    1.20 (0.96-1.50)  0.117 
LIG3 rs2074522 6.15 (1.1-31.94)  0.025    1.16 (0.78-1.73)  0.461   6.10 (1.1-31.66)  0.021  1.26 (0.88-1.81)  0.217 6.08 (1.1-32.23)  0.032 1.21 (0.80-1.82)  0.371   6.0 (1.14-31.53)  0.023    1.30 (0.90-1.89)  0.168 
XPC rs2228000 0.74 (0.44-1.26)  0.299 0.69 (0.51-0.92)  0.013  0.89 (0.53-1.49)  0.653 0.78 (0.62-0.98)  0.034 0.78 (0.45-1.35)  0.374 0.69 (0.51-0.94)  0.017    0.94 (0.55-1.59)  0.808 0.79 (0.62-1.01)  0.052 
MSH6 rs2348244 0.40 (0.09-1.84)  0.363   0.69 (0.48-0.99)  0.039 0.43 (0.10-1.97)  0.237 0.69 (0.50-0.97)  0.029 0.43 (0.09-2.00)  0.284 0.74 (0.51-1.07)  0.106  0.46 (0.10-2.12)  0.279    0.74 (0.53-1.04)  0.080 
ERCC3 rs4150416 0.83 (0.49-1.39)  0.520 0.72 (0.54-0.97)  0.032  0.98 (0.59-1.61)  0.922 0.82 (0.65-1.03)  0.092 0.77 (0.45-1.32)  0.343 0.68 (0.50-0.92)  0.013    0.94 (0.56-1.57)  0.815 0.79 (0.62-1.00)  0.053 
BRIP1 rs4986764 0.56 (0.34-0.93)  0.025 0.99 (0.73-1.34)  0.950 0.52 (0.33-0.82)  0.003    0.85 (0.68-1.05)  0.127 0.53 (0.30-0.87)  0.013  0.95 (0.69-1.31)  0.751 0.48 (0.29-0.78)  0.001   0.82 (0.65-1.02)  0.074 
EXO1 rs735943 0.69 (0.44-1.05)  0.104 0.94 (0.68-1.30)  0.723 0.65 (0.45-0.95)  0.022 0.85 (0.69-1.05)  0.124 0.68 (0.44-1.07)  0.097 0.93 (0.66-1.30)  0.672  0.66 (0.45-0.97)  0.032    0.85 (0.68-1.05)  0.133 
TP53 rs9894946 0.48 (0.16-1.45)  0.242 0.71 (0.51-1.00)  0.047   0.52 (0.181.56)  0.216 0.73 (0.54-0.98)  0.034 0.37 (0.11-1.29)  0.119  0.71 (0.50-1.02)  0.057    0.40 (0.12-1.38)  0.111 0.71 (0.52-0.98)  0.032 
Univariate analysis Multivariate analysis* 
DIFFUSE GC 
Codominant Dominant Recessive Log-additive Codominant Dominant Recessive Log-Additive 
Gen db SNP ID OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)  P value OR (95% CI)   P value OR (95% CI)   P value 
TP53 rs1042522 0.83 (0.42-1.65)  0.738  0.63 (0.45-0.89)  0.007  0.92 (0.57-1.47)  0.730 0.74 (0.56-0.98)  0.032 1.05 (0.52-2.12)  0.881    0.64 (0.44-0.92)  0.015   1.01 (0.52-1.98)  0.967 0.77 (0.57-1.05) 0.092 
RAD52 rs11226 1.73 (1.03-2.89)  0.041    1.49 (1.01-2.21)  0.041  1.40 (0.90-2.18)  0.145 1.32 (1.03-1.70)  0.030 1.72 (0.99-2.98)  0.052   1.36 (0.90-2.05)  0.141  1.51 (0.94-2.44)  0.095    1.30 (0.99-1.71)  0.055 
APEX1 rs1130409 0.66 (0.41-1.04)  0.082 0.65 (0.46-0.93)  0.020 0.85 (0.57-1.28)  0.432 0.79 (0.63-1.00)  0.052 0.57 (0.35-0.95) 0.030 0.61 (0.41-0.89)  0.011  0.76 (0.49-1.19)  0.222  0.74 (0.58-0.96)  0.019 
POLG rs176641 0.96 (0.53-1.74)   1.00 1.44 (1.02-2.04)  0.038 0.74 (0.43-1.30)  0.283 1.14 (0.89-1.46)  0.314 0.96 (0.51-1.81)  0.891 1.41 (0.97-2.04)  0.069  0.75 (0.42-1.37)  0.342 1.13 (0.86-1.47)  0.374 
XRCC3 rs1799794 0.32 (0.11-0.91)  0.023 0.95 (0.68-1.33)  0.679  0.31 (0.11-0.88)  0.010 0.85 (0.64-1.13)  0.248 0.34 (0.12-0.99)  0.047 0.88 (0.61-1.26)  0.481 0.34 (0.12-0.98)  0.023  0.81 (0.59-1.09)  0.163 
XRCC3 rs861528 2.09 (1.04-4.18)   0.040 1.92 (1.34-2.75) 0.0003 1.57 (0.81-3.07)  0.197 1.62 (1.23-2.14) 0.0007 2.45 (1.18-5.07)  0.016 2.11 (1.43-3.12) 0.0001   1.75 (0.87-3.51)  0.128 1.75 (1.30-2.37) 0.0002 
XRCC3 rs861531 1.62 (0.97-2.70)  0.076 1.60 (1.11-2.31)  0.010 1.22 (0.78-1.92)  0.384 1.32 (1.03-1.68)  0.026 1.76 (1.01-3.09)  0.047  1.89 (1.26-2.84)  0.001    1.17 (0.72-1.89)  0.536   1.39 (1.07-1.81)  0.012 
OR, odds ratio; 95% CI, 95% confidence interval.  
ORs and 95% CI in the multivariate analysis were adjusted for age, gender, H. pylori infection, smoking habit, and family history of GC. 
P values < 0.05 are highlighted in bold. 
Supplementary Table 7: Association of DNA repair gene polymorphisms with GC risk. Stratified analysis by 
age. 
Age < 50 years  Age > 50 years 
  Log-additive genetic model Log-additive genetic model 
   95% CI    95% CI   
db SNP ID Gen ORa Lower Upper P-value FDRb ORa Lower Upper P-value FDRb 
rs10079641 MSH3 1.06 0.43 2.65 0.900 0.989 0.97 0.74 1.29 0.845 0.983 
rs1042522 TP53 0.91 0.45 1.84 0.797 0.942 0.77 0.63 0.93 0.006 0.334 
rs1047768 ERCC5 0.76 0.44 1.33 0.334 0.796 0.95 0.80 1.12 0.531 0.828 
rs1047840 EXO1 1.10 0.87 1.39 0.431 0.975 0.85 0.72 1.01 0.066 0.509 
rs1048771 RAD54L 1.04 0.71 1.52 0.839 0.796 1.09 0.83 1.44 0.524 0.828 
rs1051677 XRCC5 0.75 0.33 1.71 0.317 0.796 1.18 0.87 1.60 0.276 0.766 
rs1051685 XRCC5 0.61 0.27 1.42 0.230 0.796 1.09 0.83 1.44 0.533 0.828 
rs1052133 OGG1 0.98 0.53 1.82 0.951 0.989 0.93 0.76 1.15 0.507 0.828 
rs1059262 ALKBH2 1.08 0.51 2.27 0.849 0.975 0.90 0.73 1.11 0.319 0.771 
rs1060915 BRCA1 1.24 0.67 2.29 0.497 0.839 1.09 0.91 1.30 0.374 0.776 
rs11226 RAD52 1.29 0.67 2.50 0.448 0.839 1.21 1.01 1.43 0.033 0.477 
rs1130409 APEX1 1.04 0.57 1.74 0.998 1 0.90 0.76 1.06 0.193 0.631 
rs1136410 PARP1 1.55 0.66 3.63 0.394 0.805 1.18 0.92 1.52 0.181 0.616 
rs13180316 XRCC4 1.51 0.81 2.82 0.186 0.796 0.96 0.8 1.16 0.687 0.916 
rs13181 ERCC2 0.66 0.38 1.14 0.132 0.796 1.15 0.97 1.37 0.110 0.595 
rs1346044 WRN 0.92 0.46 1.82 0.862 0.975 0.87 0.71 1.06 0.174 0.616 
rs144848 BRCA2 1.02 0.56 1.85 0.944 0.989 1.10 0.91 1.33 0.310 0.771 
rs1478485 XRCC4 0.68 0.38 1.21 0.187 0.796 1.14 0.96 1.35 0.144 0.616 
rs1540354 MLH1 1.40 0.55 3.57 0.654 0.855 0.88 0.68 1.13 0.320 0.771 
rs1614984 TP53 0.65 0.36 1.19 0.159 0.796 1.19 0.99 1.42 0.057 0.477 
rs1618536 ERCC2 0.79 0.44 1.42 0.423 0.839 0.93 0.78 1.09 0.367 0.776 
rs1650697 MSH3 0.96 0.51 1.80 0.904 0.989 0.91 0.74 1.10 0.321 0.771 
rs174538 FEN1 0.99 0.51 1.92 0.977 0.996 0.99 0.83 1.20 0.953 0.983 
rs175080 MLH3 0.86 0.49 1.50 0.585 0.845 1.04 0.88 1.23 0.628 0.871 
rs1760944 APEX1 1.02 0.57 1.85 0.944 0.989 1.01 0.84 1.22 0.901 0.983 
rs17655 ERCC5 1.16 0.65 2.05 0.617 0.855 0.79 0.65 0.96 0.017 0.477 
rs176641 POLG 1.10 0.62 1.95 0.751 0.942 1.19 0.99 1.41 0.057 0.477 
rs1776148 EXO1 1.28 0.73 2.26 0.388 0.805 0.96 0.81 1.14 0.626 0.871 
rs1799793 ERCC2 0.76 0.45 1.28 0.300 0.796 1.15 0.96 1.37 0.131 0.616 
rs1799794 XRCC3 0.79 0.41 1.50 0.465 0.839 0.94 0.78 1.14 0.556 0.828 
rs1799796 XRCC3 0.72 0.36 1.43 0.345 0.796 0.91 0.75 1.12 0.373 0.776 
rs1799801 ERCC4 0.75 0.42 1.34 0.325 0.796 0.92 0.77 1.10 0.343 0.776 
rs1799955 BRCA2 0.92 0.47 1.80 0.799 0.942 0.98 0.79 1.20 0.827 0.983 
rs1799966 BRCA1 1.24 0.67 2.29 0.497 0.839 1.05 0.88 1.26 0.609 0.871 
rs1799977 MLH1 0.69 0.38 1.24 0.206 0.796 1.01 0.85 1.21 0.903 0.983 
rs1800067 ERCC4 0.62 0.24 1.61 0.522 0.845 0.97 0.75 1.27 0.840 0.983 
rs1800389 WRN 0.87 0.45 1.67 0.740 0.942 0.88 0.73 1.05 0.161 0.616 
rs1800734 MLH1 1.39 0.74 2.62 0.301 0.796 0.99 0.81 1.19 0.881 0.983 
rs1800935 MSH6 0.97 0.53 1.78 0.921 0.989 1.15 0.95 1.39 0.159 0.616 
rs1800975 XPA 0.76 0.44 1.29 0.299 0.796 0.95 0.79 1.14 0.570 0.832 
rs1801406 BRCA2 0.86 0.44 1.68 0.659 0.889 0.90 0.75 1.09 0.287 0.771 
rs1801516 ATM 1.95 0.74 5.15 0.372 0.796 1.09 0.86 1.38 0.491 0.828 
rs1802904 ATR 1.41 0.60 3.27 0.602 0.845 1.11 0.87 1.43 0.398 0.776 
rs1805386 LIG4 0.98 0.47 2.01 0.949 0.989 0.97 0.77 1.22 0.785 0.983 
rs1805388 LIG4 1.45 0.63 3.35 0.402 0.839 1.09 0.85 1.4 0.512 0.828 
rs1805794 NBS1 1.29 0.74 2.25 0.368 0.796 1.02 0.86 1.22 0.798 0.983 
rs1981928 MSH2 0.71 0.37 1.34 0.288 0.796 1.01 0.84 1.23 0.898 0.983 
rs2020911 MSH6 0.93 0.51 1.68 0.802 0.942 0.98 0.82 1.16 0.801 0.983 
rs2040639 XRCC2 1.46 0.85 2.51 0.172 0.796 0.85 0.72 1 0.053 0.477 
rs2048718 BRIP1 1.10 0.62 1.98 0.737 0.942 0.93 0.78 1.1 0.402 0.776 
rs20580 LIG1 1.22 0.74 2.04 0.435 0.839 1.06 0.9 1.25 0.473 0.828 
rs2074522 LIG3 0.98 0.34 2.72 1 1 1.32 0.99 1.76 0.054 0.477 
rs2075685 XRCC4 0.72 0.41 1.27 0.254 0.796 1.09 0.92 1.3 0.314 0.771 
rs207906 XRCC5 0.65 0.29 1.45 0.288 0.796 1 0.77 1.28 0.974 0.983 
rs2228000 XPC 0.70 0.38 1.29 0.251 0.796 0.83 0.69 0.99 0.040 0.477 
rs2228001 XPC 0.91 0.51 1.63 0.757 0.942 0.99 0.84 1.18 0.953 0.983 
rs2228006 PMS2 0.85 0.37 1.96 0.553 0.845 1.11 0.88 1.4 0.396 0.776 
rs2238463 ERCC4 0.66 0.36 1.22 0.180 0.796 0.84 0.71 1 0.049 0.477 
rs2252775 RAD50 1.20 0.58 2.46 0.262 0.796 1.01 0.82 1.26 0.895 0.983 
rs2272615 POLB 0.62 0.27 1.38 0.348 0.796 1.01 0.78 1.30 0.948 0.983 
rs2286940 MLH1 0.81 0.46 1.44 0.478 0.839 1.04 0.88 1.23 0.642 0.878 
rs2303428 MSH2 1.76 0.81 3.81 0.178 0.796 1.09 0.82 1.44 0.560 0.828 
rs2308321 MGMT 0.98 0.36 2.65 0.775 0.942 0.91 0.68 1.21 0.510 0.828 
rs2345060 PMS2 0.65 0.34 1.23 0.177 0.796 0.86 0.71 1.05 0.146 0.616 
rs2348244 MSH6 0.87 0.33 2.26 0.821 0.975 0.78 0.60 1.01 0.056 0.477 
rs238406 ERCC2 1.28 0.76 2.15 0.349 0.796 1 0.85 1.18 0.968 0.983 
rs2434470 ALKBH3 0.94 0.46 1.89 0.858 0.975 0.86 0.70 1.04 0.126 0.616 
rs2440 XRCC5 1.73 0.95 3.18 0.070 0.796 0.99 0.83 1.17 0.890 0.983 
rs25487 XRCC1 1.12 0.66 1.89 0.677 0.903 0.86 0.73 1.02 0.085 0.572 
rs26279 MSH3 1.34 0.70 2.56 0.368 0.796 1 0.84 1.19 0.989 0.989 
rs26779 MSH3 0.87 0.50 1.49 0.603 0.845 0.86 0.72 1.02 0.081 0.572 
rs293794 OGG1 0.46 0.21 1.02 0.119 0.796 1.09 0.87 1.36 0.469 0.828 
rs3136038 ERCC4 0.66 0.35 1.22 0.176 0.796 0.84 0.71 1.01 0.057 0.477 
rs3136228 MSH6 1.17 0.68 1.99 0.574 0.845 1.08 0.91 1.29 0.387 0.776 
rs3212948 ERCC1 0.86 0.50 1.48 0.579 0.845 1.02 0.86 1.21 0.807 0.983 
rs3212961 ERCC1 0.98 0.43 2.23 0.821 0.954 1.08 0.84 1.40 0.556 0.828 
rs3212986 ERCC1 0.81 0.43 1.52 0.505 0.839 1.01 0.83 1.23 0.906 0.983 
rs3213245 XRCC1 0.70 0.37 1.34 0.280 0.796 1.11 0.94 1.31 0.206 0.637 
rs3218536 XRCC2 1.50 0.66 3.39 0.571 0.845 1.01 0.76 1.35 0.942 0.983 
rs3219489 MUTYH 0.69 0.36 1.35 0.277 0.796 0.92 0.76 1.12 0.398 0.776 
rs3626 PCNA 1.55 0.66 3.64 0.570 0.845 0.89 0.69 1.15 0.372 0.776 
rs3730668 POLI 1.22 0.70 2.13 0.476 0.839 0.96 0.81 1.14 0.665 0.898 
rs3793784 ERCC6 0.72 0.42 1.24 0.233 0.796 0.94 0.79 1.11 0.440 0.805 
rs4150416 ERCC3 1.12 0.61 2.06 0.715 0.930 0.82 0.68 0.98 0.032 0.477 
rs4150441 ERCC3 0.73 0.41 1.28 0.270 0.796 1.12 0.94 1.33 0.207 0.637 
rs4150474 ERCC3 0.92 0.48 1.75 0.797 0.942 0.87 0.71 1.06 0.156 0.616 
rs4234259 MLH1 0.77 0.43 1.38 0.376 0.796 1.03 0.87 1.21 0.735 0.968 
rs4253160 ERCC6 0.74 0.43 1.28 0.275 0.796 0.93 0.79 1.10 0.385 0.776 
rs4968451 BRIP1 0.70 0.31 1.56 0.589 0.845 0.91 0.73 1.14 0.421 0.785 
rs4986764 BRIP1 0.64 0.35 1.19 0.156 0.796 0.87 0.73 1.03 0.102 0.577 
rs4987876 ATM 0.26 0.07 0.93 0.049 0.796 0.97 0.73 1.28 0.822 0.983 
rs569143 MRE11A 0.72 0.43 1.20 0.204 0.796 0.90 0.76 1.07 0.224 0.655 
rs5744934 POLE 0.98 0.48 1.98 0.953 0.989 1.06 0.85 1.31 0.629 0.871 
rs601341 MRE11A 0.70 0.41 1.19 0.187 0.796 0.89 0.75 1.06 0.183 0.616 
rs6413436 RAD52 1.18 0.64 2.19 0.601 0.845 1.14 0.96 1.36 0.135 0.616 
rs664143 ATM 0.96 0.55 1.69 0.892 0.989 0.86 0.72 1.02 0.091 0.577 
rs7182283 NEIL1 0.82 0.47 1.43 0.484 0.839 0.93 0.79 1.10 0.416 0.785 
rs735943 EXO1 1.10 0.67 1.81 0.704 0.928 0.91 0.77 1.07 0.248 0.704 
rs7797466 PMS2 2.02 0.93 4.38 0.136 0.796 1.03 0.82 1.29 0.816 0.983 
rs799917 BRCA1 1.16 0.62 2.17 0.633 0.866 1.06 0.88 1.26 0.554 0.828 
rs8305 POLI 1.57 0.79 3.13 0.197 0.796 1.12 0.93 1.35 0.224 0.655 
rs861528 XRCC3 1.86 0.97 3.54 0.055 0.796 1.15 0.94 1.42 0.172 0.616 
rs861531 XRCC3 1.37 0.76 2.48 0.289 0.796 1.06 0.89 1.26 0.530 0.828 
rs861539 XRCC3 1.20 0.67 2.14 0.542 0.845 1.01 0.85 1.20 0.939 0.983 
rs9350 EXO1 2.19 1.03 4.68 0.035 0.796 0.82 0.65 1.04 0.099 0.577 
rs963248 XRCC4 1.22 0.57 2.57 0.242 0.796 1.01 0.81 1.27 0.908 0.983 
rs9876116 MLH1 0.81 0.46 1.43 0.467 0.839 1 0.84 1.18 0.965 0.983 
rs9894946 TP53 1.62 0.72 3.65 0.310 0.796 0.65 0.51 0.83 0.001 0.057 
GC, gastric cancer; OR, odds ratio; CI, confidence interval. 
aORs adjusted by gender, Helicobacter pylori infection, smoking, and family history of gastric cancer. 
bQFDR-values obtained after applying the False Discovery Rate (FDR) test.  
P-values <0.05 are highlighted in bold. 
Supplementary Table 8: Association of DNA repair polymorphisms with gastric cancer risk. Stratified 
analysis by gender. 
Female Gender Male Gender 
  Log-additive genetic model Log-additive genetic model 
   95% CI    95% CI   
db SNP ID Gen ORa Lower Upper P-value FDRb ORa Lower Upper P-value FDRb 
rs10079641 MSH3 0.86 0.53 1.39 0.538 0.966 1.04 0.75 1.43 0.816 0.997 
rs1042522 TP53 0.79 0.55 1.13 0.190 0.875 0.72 0.49 1.05 0.092 0.588 
rs1047768 ERCC5 0.89 0.67 1.20 0.449 0.966 0.95 0.78 1.15 0.579 0.914 
rs1047840 EXO1 1.06 0.79 1.42 0.695 0.983 0.84 0.69 1.03 0.093 0.588 
rs1048771 RAD54L 1.16 0.79 1.71 0.447 0.966 0.79 0.57 1.10 0.155 0.685 
rs1051677 XRCC5 0.83 0.48 1.43 0.599 0.966 1.25 0.9 1.75 0.183 0.710 
rs1051685 XRCC5 1.03 0.63 1.69 0.900 0.983 0.98 0.72 1.35 0.910 0.997 
rs1052133 OGG1 0.96 0.68 1.36 0.817 0.983 0.93 0.73 1.17 0.529 0.914 
rs1059262 ALKBH2 1.06 0.74 1.52 0.757 0.983 0.85 0.66 1.09 0.189 0.710 
rs1060915 BRCA1 0.89 0.66 1.21 0.453 0.966 1.21 0.98 1.50 0.072 0.556 
rs11226 RAD52 1.29 0.95 1.76 0.107 0.875 1.18 0.97 1.44 0.099 0.588 
rs1130409 APEX1 1 0.76 1.31 0.999 0.999 0.86 0.71 1.04 0.125 0.612 
rs1136410 PARP1 1.33 1.02 1.77 0.044 0.642 1.05 0.79 1.40 0.730 0.950 
rs13180316 XRCC4 1.12 0.82 1.53 0.476 0.966 0.95 0.76 1.18 0.615 0.914 
rs13181 ERCC2 1.21 0.9 1.62 0.216 0.875 1.05 0.86 1.28 0.641 0.917 
rs1346044 WRN 0.97 0.67 1.39 0.854 0.983 0.84 0.66 1.05 0.130 0.612 
rs144848 BRCA2 1.08 0.8 1.47 0.608 0.966 1.10 0.88 1.38 0.395 0.832 
rs1478485 XRCC4 1.03 0.77 1.37 0.850 0.983 1.12 0.92 1.37 0.267 0.774 
rs1540354 MLH1 1.07 0.68 1.69 0.761 0.983 0.85 0.64 1.13 0.266 0.774 
rs1614984 TP53 1.12 0.86 1.45 0.407 0.944 1.03 0.83 1.26 0.802 0.997 
rs1618536 ERCC2 1.18 0.89 1.57 0.258 0.875 0.95 0.78 1.15 0.595 0.914 
rs1650697 MSH3 1.28 0.91 1.81 0.159 0.875 0.79 0.63 0.99 0.039 0.503 
rs174538 FEN1 0.91 0.66 1.26 0.575 0.966 1.04 0.84 1.28 0.744 0.957 
rs175080 MLH3 1.18 0.88 1.57 0.279 0.875 0.97 0.80 1.17 0.729 0.950 
rs1760944 APEX1 0.99 0.72 1.37 0.969 0.983 1.02 0.83 1.26 0.855 0.997 
rs17655 ERCC5 0.81 0.57 1.14 0.222 0.875 0.83 0.67 1.03 0.085 0.576 
rs176641 POLG 1.06 0.78 1.43 0.730 0.983 1.23 1.01 1.51 0.040 0.503 
rs1776148 EXO1 1.03 0.76 1.40 0.831 0.983 0.96 0.79 1.17 0.694 0.925 
rs1799793 ERCC2 1.35 1.01 1.82 0.047 0.642 0.98 0.81 1.22 0.973 0.997 
rs1799794 XRCC3 0.98 0.70 1.37 0.896 0.983 0.91 0.73 1.13 0.397 0.832 
rs1799796 XRCC3 0.92 0.66 1.29 0.639 0.983 0.88 0.70 1.12 0.298 0.785 
rs1799801 ERCC4 0.87 0.64 1.19 0.385 0.944 0.91 0.74 1.12 0.392 0.832 
rs1799955 BRCA2 0.91 0.64 1.29 0.591 0.966 1.01 0.79 1.28 0.972 0.997 
rs1799966 BRCA1 0.88 0.65 1.19 0.403 0.944 1.16 0.94 1.44 0.159 0.685 
rs1799977 MLH1 0.91 0.68 1.22 0.537 0.966 1.01 0.82 1.25 0.901 0.997 
rs1800067 ERCC4 0.99 0.63 1.56 0.974 0.983 0.92 0.68 1.25 0.588 0.914 
rs1800389 WRN 0.87 0.64 1.18 0.366 0.944 0.89 0.72 1.11 0.312 0.801 
rs1800734 MLH1 1.01 0.73 1.41 0.972 0.983 1.02 0.82 1.27 0.863 0.997 
rs1800935 MSH6 1.01 0.73 1.40 0.963 0.983 1.19 0.95 1.48 0.122 0.612 
rs1800975 XPA 0.90 0.66 1.21 0.473 0.966 0.94 0.77 1.16 0.575 0.914 
rs1801406 BRCA2 0.88 0.64 1.21 0.420 0.944 0.91 0.73 1.14 0.408 0.832 
rs1801516 ATM 1.13 0.77 1.66 0.537 0.966 1.12 0.84 1.5 0.427 0.854 
rs1802904 ATR 1.20 0.78 1.85 0.399 0.944 1.1 0.83 1.47 0.497 0.886 
rs1805386 LIG4 1.03 0.69 1.53 0.893 0.983 0.95 0.73 1.23 0.673 0.925 
rs1805388 LIG4 1.06 0.68 1.64 0.800 0.983 1.14 0.86 1.53 0.365 0.832 
rs1805794 NBS1 1.18 0.87 1.61 0.285 0.875 0.99 0.81 1.22 0.934 0.997 
rs1981928 MSH2 0.93 0.66 1.32 0.698 0.983 1 0.81 1.25 0.980 0.997 
rs2020911 MSH6 0.78 0.58 1.06 0.108 0.875 1.08 0.88 1.31 0.478 0.886 
rs2040639 XRCC2 0.91 0.68 1.22 0.539 0.966 0.88 0.73 1.07 0.191 0.710 
rs2048718 BRIP1 0.84 0.64 1.12 0.234 0.875 1.01 0.81 1.23 0.991 0.997 
rs20580 LIG1 0.82 0.62 1.09 0.168 0.875 1.22 1.01 1.47 0.042 0.503 
rs2074522 LIG3 1.27 0.88 1.84 0.197 0.875 1.13 0.8 1.59 0.500 0.886 
rs2075685 XRCC4 1.14 0.85 1.53 0.381 0.944 1.02 0.83 1.24 0.870 0.997 
rs207906 XRCC5 0.89 0.57 1.39 0.608 0.966 0.99 0.74 1.31 0.927 0.997 
rs2228000 XPC 0.78 0.57 1.08 0.133 0.875 0.83 0.68 1.02 0.077 0.556 
rs2228001 XPC 0.84 0.62 1.13 0.252 0.875 1.06 0.87 1.3 0.559 0.914 
rs2228006 PMS2 1.32 0.87 2.01 0.184 0.875 0.99 0.77 1.31 0.997 0.997 
rs2238463 ERCC4 0.85 0.63 1.15 0.301 0.878 0.81 0.66 0.99 0.042 0.503 
rs2252775 RAD50 0.85 0.58 1.23 0.384 0.944 1.12 0.87 1.43 0.378 0.832 
rs2272615 POLB 1.13 0.72 1.77 0.592 0.966 0.9 0.67 1.2 0.475 0.886 
rs2286940 MLH1 0.98 0.75 1.29 0.889 0.983 1.04 0.86 1.27 0.686 0.925 
rs2303428 MSH2 1.01 0.63 1.63 0.960 0.983 1.22 0.89 1.66 0.216 0.728 
rs2308321 MGMT 0.89 0.52 1.52 0.834 0.983 0.92 0.67 1.28 0.625 0.914 
rs2345060 PMS2 0.91 0.64 1.28 0.571 0.966 0.82 0.65 1.02 0.077 0.556 
rs2348244 MSH6 0.66 0.43 0.99 0.048 0.642 0.86 0.64 1.17 0.350 0.832 
rs238406 ERCC2 1.06 0.81 1.39 0.681 0.983 1.06 0.88 1.27 0.569 0.914 
rs2434470 ALKBH3 0.81 0.57 1.17 0.259 0.875 0.88 0.7 1.11 0.272 0.774 
rs2440 XRCC5 1.10 0.82 1.46 0.525 0.966 10.1 0.82 1.22 0.996 0.997 
rs25487 XRCC1 1.03 0.77 1.37 0.839 0.983 0.83 0.68 1.02 0.051 0.504 
rs26279 MSH3 1.18 0.88 1.59 0.269 0.875 0.95 0.78 1.16 0.623 0.914 
rs26779 MSH3 0.97 0.72 1.31 0.864 0.983 0.81 0.66 0.99 0.038 0.503 
rs293794 OGG1 0.85 0.57 1.26 0.420 0.944 1.10 0.85 1.42 0.489 0.886 
rs3136038 ERCC4 0.85 0.62 1.15 0.292 0.875 0.82 0.66 10.2 0.051 0.504 
rs3136228 MSH6 0.99 0.73 1.33 0.939 0.983 1.14 0.93 1.40 0.204 0.712 
rs3212948 ERCC1 1.15 0.86 1.55 0.343 0.944 0.95 0.78 1.15 0.583 0.914 
rs3212961 ERCC1 1.27 0.81 1.99 0.152 0.875 0.99 0.74 1.33 0.971 0.997 
rs3212986 ERCC1 1.22 0.87 1.73 0.248 0.875 0.91 0.73 1.14 0.401 0.832 
rs3213245 XRCC1 1.01 0.75 1.36 0.954 0.983 1.11 0.92 1.34 0.280 0.774 
rs3218536 XRCC2 1.01 0.61 1.65 0.847 0.983 1.08 0.78 1.49 0.645 0.917 
rs3219489 MUTYH 0.83 0.59 1.15 0.262 0.875 0.93 0.75 1.17 0.552 0.914 
rs3626 PCNA 0.94 0.62 1.42 0.773 0.983 0.93 0.69 1.25 0.627 0.914 
rs3730668 POLI 0.99 0.73 1.35 0.967 0.983 0.98 0.80 1.19 0.835 0.997 
rs3793784 ERCC6 0.95 0.72 1.25 0.719 0.983 0.9 0.73 1.09 0.274 0.774 
rs4150416 ERCC3 1.23 0.98 1.56 0.075 0.833 0.97 0.79 1.20 0.796 0.997 
rs4150441 ERCC3 1.23 0.91 1.67 0.177 0.875 1.02 0.84 1.24 0.865 0.997 
rs4150474 ERCC3 1.21 0.95 1.55 0.119 0.875 1.02 0.81 1.28 0.880 0.997 
rs4234259 MLH1 0.94 0.72 1.24 0.676 0.983 1.04 0.86 1.27 0.686 0.925 
rs4253160 ERCC6 0.87 0.66 1.15 0.319 0.908 0.93 0.77 1.13 0.481 0.886 
rs4968451 BRIP1 0.90 0.64 1.28 0.569 0.966 0.89 0.67 1.17 0.396 0.832 
rs4986764 BRIP1 0.79 0.59 1.06 0.112 0.875 0.88 0.72 1.07 0.199 0.712 
rs4987876 ATM 1.24 0.78 1.98 0.368 0.944 0.77 0.55 1.07 0.119 0.612 
rs569143 MRE11A 1.04 0.78 1.38 0.781 0.983 1.23 1.01 1.50 0.036 0.503 
rs5744934 POLE 1.14 0.79 1.63 0.485 0.966 1.01 0.78 1.30 0.965 0.997 
rs601341 MRE11A 1.06 0.79 1.42 0.714 0.983 1.10 0.86 1.41 0.462 0.886 
rs6413436 RAD52 1.19 0.87 1.62 0.272 0.875 1.13 0.92 1.37 0.240 0.773 
rs664143 ATM 0.80 0.60 1.08 0.144 0.875 0.90 0.74 1.11 0.325 0.816 
rs7182283 NEIL1 0.94 0.70 1.25 0.653 0.983 0.92 0.76 1.11 0.381 0.832 
rs735943 EXO1 0.98 0.75 1.32 0.974 0.983 0.89 0.74 1.08 0.243 0.773 
rs7797466 PMS2 1.25 0.84 1.85 0.272 0.875 1.02 0.79 1.33 0.858 0.997 
rs799917 BRCA1 0.84 0.62 1.14 0.259 0.875 1.19 0.96 1.47 0.104 0.588 
rs8305 POLI 0.98 0.71 1.36 0.907 0.983 1.23 0.99 1.53 0.057 0.517 
rs861528 XRCC3 1.39 0.97 1.98 0.069 0.833 1.13 0.9 1.43 0.298 0.785 
rs861531 XRCC3 1.08 0.81 1.46 0.596 0.966 1.08 0.88 1.32 0.461 0.886 
rs861539 XRCC3 1.03 0.77 1.38 0.837 0.983 1.02 0.83 1.24 0.869 0.997 
rs9350 EXO1 1.10 0.74 1.65 0.640 0.983 0.83 0.64 1.08 0.165 0.685 
rs963248 XRCC4 0.97 0.65 1.43 0.866 0.983 1.06 0.82 1.37 0.675 0.925 
rs9876116 MLH1 0.93 0.71 1.21 0.576 0.966 1.01 0.83 1.23 0.919 0.997 
rs9894946 TP53 0.78 0.51 1.20 0.158 0.875 0.77 0.62 0.96 0.017 0.503 
OR, odds ratio; CI, confidence interval. 
aORs adjusted by age, Helicobacter pylori infection, smoking status, and family history of gastric cancer. 
bQFDR-values obtained after applying the False Discovery Rate (FDR) test.  
P-values <0.05 are highlighted in bold. 
Supplementary Table 9: Association of DNA repair gene polymorphisms with gastric cancer risk. Stratified 
analysis by smoking status (never smokers / current smokers). 
Never smokers  Current smokers 
  Log-additive genetic model Log-additive genetic model 
   95% CI    95% CI   
db SNP ID Gen ORa Lower Upper P-value FDRb ORa Lower Upper P-value FDRb 
rs10079641 MSH3 0.90 0.62 1.33 0.611 0.957 1.50 0.80 2.83 0.195 0.994 
rs1042522 TP53 0.81 0.62 1.06 0.124 0.810 0.60 0.38 0.96 0.031 0.943 
rs1047768 ERCC5 0.88 0.71 1.10 0.276 0.927 1.02 0.71 1.48 0.900 0.994 
rs1047840 EXO1 0.81 0.64 1.02 0.076 0.810 1.11 0.75 1.66 0.600 0.994 
rs1048771 RAD54L 1.24 0.87 1.76 0.232 0.927 0.79 0.40 1.57 0.568 0.994 
rs1051677 XRCC5 1.39 0.91 2.12 0.173 0.810 0.76 0.40 1.45 0.477 0.994 
rs1051685 XRCC5 1.01 0.69 1.45 0.989 0.990 0.90 0.46 1.73 0.743 0.994 
rs1052133 OGG1 0.86 0.65 1.13 0.274 0.927 1.09 0.67 1.78 0.720 0.994 
rs1059262 ALKBH2 0.90 0.67 1.21 0.492 0.949 1.10 0.68 1.78 0.689 0.994 
rs1060915 BRCA1 1.09 0.85 1.39 0.492 0.949 1.01 0.67 1.51 0.965 0.994 
rs11226 RAD52 1.25 0.98 1.58 0.072 0.810 1.31 0.87 1.96 0.188 0.994 
rs1130409 APEX1 0.93 0.75 1.16 0.518 0.949 0.80 0.54 1.19 0.267 0.994 
rs1136410 PARP1 1.36 0.97 1.91 0.076 0.810 0.91 0.52 1.58 0.727 0.994 
rs13180316 XRCC4 0.97 0.76 1.23 0.782 0.987 0.91 0.58 1.44 0.702 0.994 
rs13181 ERCC2 1.15 0.91 1.46 0.234 0.927 1.03 0.69 1.55 0.884 0.994 
rs1346044 WRN 0.96 0.72 1.27 0.765 0.987 1.03 0.65 1.61 0.907 0.994 
rs144848 BRCA2 1.06 0.82 1.37 0.641 0.976 1.10 0.72 1.69 0.653 0.994 
rs1478485 XRCC4 1.15 0.91 1.44 0.243 0.927 0.95 0.63 1.41 0.785 0.994 
rs1540354 MLH1 0.85 0.60 1.21 0.362 0.949 1.15 0.65 2.04 0.631 0.994 
rs1614984 TP53 1.20 0.94 1.53 0.148 0.810 0.79 0.52 1.21 0.283 0.994 
rs1618536 ERCC2 1.13 0.90 1.42 0.280 0.927 0.83 0.55 1.24 0.358 0.994 
rs1650697 MSH3 1 0.77 1.30 0.990 0.990 0.58 0.37 0.91 0.016 0.943 
rs174538 FEN1 0.99 0.77 1.28 0.963 0.987 0.98 0.64 1.49 0.918 0.994 
rs175080 MLH3 1.01 0.80 1.27 0.943 0.987 0.92 0.64 1.34 0.676 0.994 
rs1760944 APEX1 0.95 0.75 1.22 0.707 0.979 1.11 0.71 1.74 0.651 0.994 
rs17655 ERCC5 0.77 0.59 1.01 0.058 0.810 1.01 0.66 1.54 0.963 0.994 
rs176641 POLG 1.08 0.85 1.37 0.554 0.949 1.58 1.04 2.42 0.031 0.943 
rs1776148 EXO1 1.01 0.80 1.29 0.914 0.987 1.09 0.74 1.62 0.662 0.994 
rs1799793 ERCC2 1.14 0.90 1.46 0.270 0.927 1.16 0.77 1.77 0.476 0.994 
rs1799794 XRCC3 0.95 0.73 1.23 0.679 0.979 0.87 0.57 1.33 0.517 0.994 
rs1799796 XRCC3 1.01 0.78 1.32 0.926 0.987 0.89 0.55 1.44 0.629 0.994 
rs1799801 ERCC4 0.93 0.73 1.18 0.536 0.949 0.82 0.55 1.25 0.360 0.994 
rs1799955 BRCA2 0.99 0.75 1.30 0.918 0.987 1.05 0.64 1.72 0.839 0.994 
rs1799966 BRCA1 1.05 0.82 1.34 0.701 0.979 1.01 0.67 1.51 0.965 0.994 
rs1799977 MLH1 0.99 0.78 1.25 0.915 0.987 0.9 0.61 1.34 0.608 0.994 
rs1800067 ERCC4 0.95 0.67 1.33 0.756 0.987 1.02 0.54 1.92 0.957 0.994 
rs1800389 WRN 0.98 0.76 1.25 0.861 0.987 0.94 0.57 1.54 0.799 0.994 
rs1800734 MLH1 0.95 0.73 1.23 0.673 0.979 1.07 0.69 1.65 0.769 0.994 
rs1800935 MSH6 1.09 0.83 1.42 0.541 0.949 1.06 0.70 1.62 0.769 0.994 
rs1800975 XPA 0.91 0.71 1.15 0.425 0.949 0.82 0.54 1.24 0.338 0.994 
rs1801406 BRCA2 0.99 0.77 1.29 0.969 0.987 1.02 0.65 1.59 0.943 0.994 
rs1801516 ATM 0.90 0.65 1.25 0.536 0.949 1.47 0.83 2.62 0.293 0.994 
rs1802904 ATR 1.18 0.85 1.65 0.318 0.949 1.35 0.72 2.52 0.536 0.994 
rs1805386 LIG4 0.98 0.72 1.34 0.895 0.987 0.81 0.48 1.36 0.424 0.994 
rs1805388 LIG4 1.36 0.96 1.91 0.079 0.810 0.91 0.50 1.65 0.133 0.994 
rs1805794 NBS1 1.07 0.84 1.35 0.603 0.957 1.03 0.69 1.55 0.872 0.994 
rs1981928 MSH2 0.98 0.75 1.28 0.884 0.987 0.76 0.50 1.14 0.176 0.994 
rs2020911 MSH6 0.92 0.73 1.17 0.501 0.949 0.99 0.66 1.47 0.950 0.994 
rs2040639 XRCC2 0.92 0.74 1.16 0.491 0.949 1.01 0.67 1.49 0.995 0.995 
rs2048718 BRIP1 1.11 0.89 1.39 0.362 0.949 1.01 0.67 1.52 0.972 0.994 
rs20580 LIG1 1.08 0.87 1.35 0.493 0.949 1.28 0.88 1.87 0.194 0.994 
rs2074522 LIG3 1.34 0.91 1.97 0.136 0.810 1.59 0.81 3.12 0.325 0.994 
rs2075685 XRCC4 1.11 0.88 1.39 0.397 0.949 0.96 0.65 1.43 0.848 0.994 
rs207906 XRCC5 0.79 0.56 1.10 0.156 0.810 1.08 0.58 2.01 0.408 0.994 
rs2228000 XPC 0.81 0.63 1.05 0.105 0.810 0.83 0.56 1.21 0.324 0.994 
rs2228001 XPC 0.88 0.69 1.11 0.280 0.927 1.09 0.74 1.62 0.667 0.994 
rs2228006 PMS2 1.26 0.92 1.73 0.150 0.810 0.85 0.51 1.40 0.517 0.994 
rs2238463 ERCC4 0.91 0.72 1.15 0.412 0.949 0.67 0.45 1 0.048 0.943 
rs2252775 RAD50 0.92 0.69 1.24 0.595 0.957 1.16 0.7 1.93 0.557 0.994 
rs2272615 POLB 1.08 0.76 1.53 0.675 0.979 0.84 0.48 1.50 0.566 0.994 
rs2286940 MLH1 1.10 0.89 1.37 0.377 0.949 0.92 0.63 1.36 0.689 0.994 
rs2303428 MSH2 0.89 0.60 1.31 0.552 0.949 0.98 0.59 1.63 0.941 0.994 
rs2308321 MGMT 1.02 0.69 1.52 0.908 0.987 1.03 0.52 2.03 0.159 0.994 
rs2345060 PMS2 0.92 0.70 1.19 0.517 0.949 0.75 0.47 1.19 0.219 0.994 
rs2348244 MSH6 0.71 0.50 1.01 0.054 0.810 1.19 0.64 2.23 0.584 0.994 
rs238406 ERCC2 1.01 0.81 1.25 0.945 0.987 1.03 0.69 1.52 0.896 0.994 
rs2434470 ALKBH3 0.78 0.59 1.04 0.089 0.810 0.74 0.49 1.13 0.162 0.994 
rs2440 XRCC5 1.02 0.81 1.27 0.887 0.987 1.34 0.90 2 0.142 0.994 
rs25487 XRCC1 0.92 0.74 1.15 0.460 0.949 0.77 0.53 1.11 0.160 0.994 
rs26279 MSH3 1.09 0.86 1.37 0.486 0.949 0.95 0.64 1.43 0.820 0.994 
rs26779 MSH3 0.92 0.73 1.17 0.505 0.949 0.67 0.45 1.01 0.052 0.943 
rs293794 OGG1 1.03 0.75 1.40 0.873 0.987 0.80 0.47 1.36 0.411 0.994 
rs3136038 ERCC4 0.91 0.71 1.15 0.414 0.949 0.66 0.44 0.99 0.043 0.943 
rs3136228 MSH6 1.04 0.82 1.32 0.757 0.987 0.98 0.66 1.44 0.906 0.994 
rs3212948 ERCC1 1.05 0.83 1.31 0.703 0.979 1.10 0.73 1.65 0.665 0.994 
rs3212961 ERCC1 1.10 0.77 1.58 0.595 0.957 1.30 0.74 2.27 0.362 0.994 
rs3212986 ERCC1 1.09 0.83 1.44 0.517 0.949 0.93 0.58 1.50 0.777 0.994 
rs3213245 XRCC1 1.01 0.81 1.27 0.929 0.987 1.27 0.86 1.88 0.228 0.994 
rs3218536 XRCC2 1.06 0.71 1.57 0.407 0.949 0.81 0.44 1.47 0.097 0.994 
rs3219489 MUTYH 0.80 0.62 1.05 0.108 0.810 1.12 0.71 1.75 0.631 0.994 
rs3626 PCNA 0.98 0.69 1.39 0.909 0.987 0.8 0.43 1.49 0.697 0.994 
rs3730668 POLI 0.91 0.72 1.15 0.423 0.949 0.99 0.66 1.48 0.955 0.994 
rs3793784 ERCC6 0.93 0.75 1.16 0.538 0.949 0.71 0.48 1.06 0.096 0.994 
rs4150416 ERCC3 0.74 0.57 0.94 0.015 0.796 0.91 0.60 1.36 0.637 0.994 
rs4150441 ERCC3 1.14 0.90 1.44 0.283 0.927 1.02 0.69 1.52 0.906 0.994 
rs4150474 ERCC3 0.86 0.70 1.12 0.215 0.927 0.92 0.60 1.41 0.696 0.994 
rs4234259 MLH1 0.92 0.74 1.14 0.431 0.949 0.94 0.64 1.38 0.751 0.994 
rs4253160 ERCC6 0.89 0.71 1.11 0.313 0.949 0.72 0.48 1.06 0.096 0.994 
rs4968451 BRIP1 1.06 0.80 1.42 0.684 0.979 0.74 0.42 1.31 0.306 0.994 
rs4986764 BRIP1 0.84 0.67 1.05 0.132 0.810 0.96 0.64 1.44 0.833 0.994 
rs4987876 ATM 1.29 0.89 1.87 0.171 0.810 0.63 0.33 1.22 0.170 0.994 
rs569143 MRE11A 0.93 0.74 1.17 0.532 0.949 0.78 0.53 1.15 0.210 0.994 
rs5744934 POLE 1.04 0.77 1.40 0.798 0.987 1.18 0.70 2 0.093 0.994 
rs601341 MRE11A 0.93 0.74 1.18 0.566 0.955 0.81 0.55 1.20 0.297 0.994 
rs6413436 RAD52 1.19 0.94 1.50 0.160 0.810 1.05 0.69 1.59 0.813 0.994 
rs664143 ATM 0.82 0.65 1.04 0.108 0.810 0.98 0.67 1.44 0.913 0.994 
rs7182283 NEIL1 0.96 0.76 1.22 0.757 0.987 0.81 0.56 1.17 0.266 0.994 
rs735943 EXO1 0.97 0.78 1.22 0.823 0.987 1 0.70 1.44 0.985 0.994 
rs7797466 PMS2 0.93 0.68 1.27 0.629 0.970 0.99 0.63 1.57 0.977 0.994 
rs799917 BRCA1 1.04 0.82 1.33 0.724 0.987 1.10 0.73 1.64 0.650 0.994 
rs8305 POLI 1.17 0.90 1.51 0.234 0.927 0.98 0.65 1.48 0.924 0.994 
rs861528 XRCC3 1.24 0.94 1.63 0.131 0.810 1.14 0.72 1.81 0.564 0.994 
rs861531 XRCC3 1.01 0.79 1.28 0.965 0.987 1.24 0.84 1.84 0.275 0.994 
rs861539 XRCC3 0.97 0.77 1.23 0.797 0.987 1.17 0.79 1.73 0.437 0.994 
rs9350 EXO1 0.98 0.71 1.34 0.883 0.987 0.81 0.49 1.32 0.399 0.994 
rs963248 XRCC4 0.97 0.71 1.33 0.869 0.987 1.19 0.73 1.93 0.489 0.994 
rs9876116 MLH1 1.06 0.85 1.31 0.597 0.957 0.87 0.59 1.28 0.467 0.994 
rs9894946 TP53 0.69 0.49 0.97 0.033 0.810 0.88 0.53 1.47 0.636 0.994 
OR, odds ratio; CI, confidence interval. 
aORs adjusted by gender, age, Helicobacter pylori infection, and family history of gastric cancer. 
bQFDR-values obtained after applying the False Discovery Rate (FDR) test.  
P-values <0.05 are highlighted in bold. 
Supplementary Table 10: Association of DNA repair gene polymorphisms with gastric cancer risk. Stratified 
analysis by family history of gastric cancer. 
Family history of GC (negative) Family history of GC (positive) 
  Log-additive genetic model Log-additive genetic model 
   95% CI    95% CI   
db SNP ID Gen ORa Lower Upper P-value FDRb ORa Lower Upper P-value FDRb 
rs10079641 MSH3 1.08 0.80 1.46 0.609 0.936 0.70 0.29 1.70 0.501 0.840 
rs1042522 TP53 0.82 0.66 1.01 0.056 0.473 0.58 0.31 1.07 0.083 0.709 
rs1047768 ERCC5 0.96 0.81 1.15 0.677 0.936 1.03 0.58 1.83 0.916 1 
rs1047840 EXO1 0.88 0.73 1.07 0.194 0.626 1.03 0.57 1.87 0.926 1 
rs1048771 RAD54L 1.06 0.79 1.41 0.714 0.952 1.19 0.41 3.46 1 1 
rs1051677 XRCC5 1.23 0.90 1.69 0.195 0.626 0.73 0.26 2.04 0.585 0.867 
rs1051685 XRCC5 0.97 0.72 1.31 0.832 0.992 1.54 0.50 4.76 0.071 0.709 
rs1052133 OGG1 1.06 0.85 1.32 0.617 0.936 1.08 0.82 1.41 0.592 0.867 
rs1059262 ALKBH2 0.92 0.73 1.16 0.494 0.889 0.81 0.39 1.66 0.564 0.867 
rs1060915 BRCA1 1.05 0.86 1.28 0.616 0.936 1.23 0.66 2.28 0.514 0.840 
rs11226 RAD52 1.13 0.87 1.46 0.360 0.806 0.79 0.45 1.39 0.408 0.819 
rs1130409 APEX1 0.85 0.71 1.01 0.070 0.473 1.41 0.81 2.45 0.217 0.757 
rs1136410 PARP1 1.19 0.90 1.57 0.220 0.626 1.52 0.67 3.46 0.672 0.931 
rs13180316 XRCC4 1.01 0.82 1.23 0.987 0.992 1.21 0.62 2.37 0.570 0.867 
rs13181 ERCC2 1.07 0.89 1.28 0.483 0.888 1.24 0.66 2.32 0.508 0.840 
rs1346044 WRN 0.91 0.73 1.13 0.395 0.806 1.06 0.49 2.28 0.885 1 
rs144848 BRCA2 1.15 0.94 1.41 0.167 0.626 1.18 0.56 2.47 0.859 1 
rs1478485 XRCC4 1.01 0.84 1.21 0.931 0.992 1.10 0.61 1.97 0.746 0.956 
rs1540354 MLH1 0.96 0.73 1.26 0.746 0.971 0.59 0.24 1.45 0.252 0.757 
rs1614984 TP53 1.11 0.92 1.35 0.267 0.642 1.47 0.81 2.67 0.194 0.757 
rs1618536 ERCC2 0.91 0.76 1.09 0.287 0.659 1.34 0.75 2.39 0.326 0.783 
rs1650697 MSH3 0.87 0.71 1.08 0.203 0.626 1.18 0.60 2.35 0.625 0.913 
rs174538 FEN1 1.01 0.83 1.23 0.924 0.992 0.89 0.47 1.71 0.731 0.956 
rs175080 MLH3 0.99 0.83 1.18 0.907 0.992 1.59 0.88 2.87 0.114 0.709 
rs1760944 APEX1 0.97 0.79 1.19 0.769 0.980 1.53 0.81 2.92 0.183 0.757 
rs17655 ERCC5 0.89 0.73 1.09 0.273 0.642 0.53 0.25 1.08 0.081 0.709 
rs176641 POLG 1.06 0.83 1.35 0.634 0.936 0.97 0.53 1.79 0.933 1 
rs1776148 EXO1 1.06 0.87 1.28 0.568 0.936 1.50 0.82 2.72 0.177 0.757 
rs1799793 ERCC2 1.09 0.90 1.32 0.386 0.806 0.74 0.42 1.32 0.309 0.783 
rs1799794 XRCC3 0.88 0.71 1.08 0.219 0.626 2.07 0.90 4.74 0.265 0.757 
rs1799796 XRCC3 0.96 0.77 1.20 0.737 0.971 0.53 0.26 1.06 0.072 0.709 
rs1799801 ERCC4 0.89 0.74 1.08 0.255 0.642 0.79 0.42 1.48 0.465 0.840 
rs1799955 BRCA2 1.05 0.84 1.31 0.693 0.936 0.47 0.21 1.02 0.062 0.709 
rs1799966 BRCA1 1.02 0.84 1.24 0.860 0.992 1.22 0.66 2.26 0.528 0.851 
rs1799977 MLH1 0.96 0.79 1.16 0.661 0.936 1.34 0.66 2.72 0.427 0.824 
rs1800067 ERCC4 0.81 0.61 1.08 0.150 0.624 1.46 0.58 3.68 0.736 0.956 
rs1800389 WRN 0.89 0.73 1.09 0.257 0.642 0.66 0.35 1.24 0.197 0.757 
rs1800734 MLH1 1.01 0.82 1.24 0.933 0.992 0.92 0.47 1.81 0.816 1 
rs1800935 MSH6 1.14 0.93 1.41 0.212 0.626 0.66 0.36 1.20 0.175 0.757 
rs1800975 XPA 0.89 0.74 1.08 0.244 0.642 0.73 0.39 1.37 0.333 0.783 
rs1801406 BRCA2 0.87 0.70 1.06 0.169 0.626 0.92 0.44 1.96 0.834 1 
rs1801516 ATM 1.21 0.94 1.57 0.144 0.624 0.84 0.37 1.88 0.677 0.931 
rs1802904 ATR 1.26 0.96 1.64 0.096 0.546 0.95 0.44 2.03 0.478 0.840 
rs1805386 LIG4 1.03 0.81 1.32 0.804 0.992 0.97 0.43 2.17 0.326 0.783 
rs1805388 LIG4 1.06 0.81 1.39 0.693 0.936 3.24 1.06 9.87 0.100 0.709 
rs1805794 NBS1 1.05 0.87 1.27 0.633 0.936 1.25 0.66 2.37 0.491 0.840 
rs1981928 MSH2 1.02 0.81 1.22 0.967 0.992 0.99 0.51 1.96 0.986 1 
rs2020911 MSH6 0.99 0.82 1.20 0.958 0.992 0.98 0.55 1.76 0.957 1 
rs2040639 XRCC2 0.93 0.77 1.11 0.395 0.806 0.97 0.55 1.71 0.918 1 
rs2048718 BRIP1 0.98 0.82 1.18 0.850 0.992 1.38 0.70 2.72 0.344 0.791 
rs20580 LIG1 1.18 0.99 1.41 0.067 0.473 0.76 0.44 1.31 0.326 0.783 
rs2074522 LIG3 1.19 0.87 1.62 0.270 0.642 1.34 0.52 3.43 1 1 
rs2075685 XRCC4 0.94 0.78 1.13 0.517 0.916 1.33 0.72 2.44 0.358 0.805 
rs207906 XRCC5 0.84 0.64 1.10 0.209 0.626 1.20 0.49 2.93 0.686 0.938 
rs2228000 XPC 0.82 0.68 0.99 0.048 0.473 1.08 0.54 2.18 0.821 1 
rs2228001 XPC 1.05 0.87 1.26 0.620 0.936 0.74 0.42 1.32 0.307 0.783 
rs2228006 PMS2 1.02 0.79 1.32 0.875 0.992 0.93 0.45 1.94 0.244 0.757 
rs2238463 ERCC4 0.84 0.69 1.01 0.061 0.473 0.62 0.34 1.14 0.123 0.709 
rs2252775 RAD50 1.01 0.80 1.26 0.971 0.992 1.40 0.65 2.99 0.377 0.814 
rs2272615 POLB 0.92 0.70 1.20 0.535 0.931 0.68 0.30 1.55 0.367 0.810 
rs2286940 MLH1 1.07 0.89 1.27 0.485 0.888 1.21 0.64 2.29 0.548 0.858 
rs2303428 MSH2 1.14 0.86 1.51 0.377 0.806 0.96 0.38 2.44 0.253 0.757 
rs2308321 MGMT 0.89 0.65 1.22 0.482 0.888 1.22 0.42 3.47 0.800 0.939 
rs2345060 PMS2 0.92 0.74 1.13 0.416 0.832 0.56 0.28 1.14 0.109 0.709 
rs2348244 MSH6 0.81 0.61 1.07 0.145 0.624 1.47 0.53 4.13 0.629 0.913 
rs238406 ERCC2 0.98 0.82 1.16 0.785 0.986 1.41 0.81 2.45 0.217 0.757 
rs2434470 ALKBH3 0.88 0.71 1.09 0.251 0.642 0.60 0.31 1.15 0.162 0.709 
rs2440 XRCC5 1.08 0.90 1.29 0.434 0.852 1.02 0.56 1.85 0.956 1 
rs25487 XRCC1 0.88 0.73 1.05 0.144 0.624 0.89 0.50 1.60 0.704 0.939 
rs26279 MSH3 0.99 0.83 1.21 0.989 0.992 1.04 0.58 1.85 0.894 1 
rs26779 MSH3 0.85 0.70 1.02 0.077 0.490 0.94 0.52 1.72 0.845 1 
rs293794 OGG1 1.01 0.80 1.28 0.925 0.992 0.83 0.37 1.86 0.648 0.922 
rs3136038 ERCC4 0.81 0.67 0.98 0.034 0.473 0.72 0.40 1.32 0.289 0.779 
rs3136228 MSH6 1.09 0.90 1.33 0.358 0.805 0.80 0.44 1.44 0.454 0.840 
rs3212948 ERCC1 1.03 0.85 1.24 0.771 0.980 0.70 0.40 1.24 0.222 0.757 
rs3212961 ERCC1 1.20 0.91 1.59 0.202 0.626 0.57 0.26 1.24 0.163 0.757 
rs3212986 ERCC1 0.98 0.79 1.22 0.869 0.992 0.76 0.39 1.46 0.409 0.819 
rs3213245 XRCC1 1.17 0.97 1.40 0.096 0.546 1.24 0.68 2.26 0.477 0.840 
rs3218536 XRCC2 1.08 0.79 1.46 0.643 0.936 0.51 0.22 1.16 0.114 0.709 
rs3219489 MUTYH 1.06 0.86 1.31 0.592 0.936 1.11 0.87 1.41 0.392 0.814 
rs3626 PCNA 0.93 0.71 1.23 0.628 0.936 0.70 0.32 1.53 0.227 0.757 
rs3730668 POLI 0.88 0.72 1.06 0.169 0.626 0.73 0.42 1.25 0.242 0.757 
rs3793784 ERCC6 0.84 0.70 1.01 0.065 0.473 1.14 0.63 2.04 0.665 0.931 
rs4150416 ERCC3 0.83 0.68 1.01 0.067 0.473 0.62 0.32 1.20 0.151 0.757 
rs4150441 ERCC3 1.04 0.87 1.25 0.662 0.936 1.66 0.86 3.19 0.125 0.709 
rs4150474 ERCC3 0.87 0.71 1.08 0.210 0.626 0.68 0.35 1.36 0.278 0.768 
rs4234259 MLH1 1.05 0.88 1.25 0.618 0.936 1.30 0.70 2.43 0.405 0.819 
rs4253160 ERCC6 0.83 0.69 0.99 0.041 0.473 0.98 0.57 1.69 0.951 1 
rs4968451 BRIP1 0.90 0.70 1.15 0.389 0.806 0.97 0.43 2.18 0.814 1 
rs4986764 BRIP1 0.86 0.72 1.04 0.113 0.583 1.10 0.59 2.06 0.753 0.956 
rs4987876 ATM 1.02 0.76 1.36 0.896 0.992 0.28 0.09 0.90 0.020 0.520 
rs569143 MRE11A 0.84 0.70 1.01 0.059 0.473 0.82 0.46 1.46 0.507 0.840 
rs5744934 POLE 1.15 0.91 1.45 0.249 0.642 0.98 0.43 2.25 0.969 1 
rs601341 MRE11A 0.87 0.72 1.05 0.147 0.624 1.01 0.58 1.73 0.989 1 
rs6413436 RAD52 1.22 1.01 1.48 0.036 0.473 0.65 0.36 1.15 0.136 0.736 
rs664143 ATM 0.83 0.69 1.01 0.055 0.473 1.39 0.77 2.49 0.266 0.757 
rs7182283 NEIL1 0.96 0.80 1.16 0.690 0.936 0.56 0.31 1.01 0.068 0.709 
rs735943 EXO1 0.93 0.78 1.12 0.455 0.878 1.48 0.79 2.77 0.211 0.757 
rs7797466 PMS2 1.07 0.85 1.36 0.560 0.936 2 0.71 5.63 0.512 0.840 
rs799917 BRCA1 1.01 0.83 1.22 0.934 0.992 1.32 0.70 2.47 0.388 0.819 
rs8305 POLI 1.25 1.02 1.53 0.032 0.473 0.60 0.31 1.15 0.123 0.709 
rs861528 XRCC3 1.20 0.96 1.49 0.112 0.583 1.05 0.54 2.03 0.881 1 
rs861531 XRCC3 1.01 0.83 1.22 0.937 0.992 0.95 0.52 1.74 0.872 1 
rs861539 XRCC3 0.95 0.79 1.15 0.622 0.936 0.86 0.47 1.56 0.619 0.913 
rs9350 EXO1 0.99 0.78 1.28 0.992 0.992 0.32 0.14 0.78 0.014 0.520 
rs963248 XRCC4 1.02 0.80 1.30 0.887 0.992 0.95 0.44 2.03 0.886 1 
rs9876116 MLH1 1.02 0.85 1.22 0.843 0.992 1.17 0.63 2.18 0.624 0.913 
rs9894946 TP53 0.77 0.56 1.04 0.092 0.546 0.83 0.61 1.13 0.229 0.757 
GC, gastric cancer; OR, odds ratio; CI, confidence interval. 
aORs adjusted by gender, age, Helicobacter pylori infection, and smoking status. 
bQFDR-values obtained after applying the False Discovery Rate (FDR) test.  
P-values <0.05 are highlighted in bold. 
 
Supplementary Table 11: Haplotypes in DNA repair genes and association with GC risk. 
Gene SNPs Haplotype Frequency HC  Frequency GC OR (95% CI)* P value 
APEX1 rs1130409 GC  0.3739 0.3529  Reference  
 rs1760944 TA 0.2579 0.2638 1.08 (0.87 - 1.33)   0.4743 
  TC 0.2505 0.2703 1.14 (0.90 - 1.45)   0.2746 
  GA 0.1177 0.1129 1.02 (0.72 - 1.43)   0.9212 
ATM rs1801516 GGC  0.3864  0.4109 Reference  
 rs4987876 GGT 0.3838 0.3544 0.86 (0.71 - 1.03)   0.0940 
 rs664143 AGC 0.1364 0.1505 1.04 (0.81 - 1.33)   0.7626 
  GTC 0.0934 0.0842 0.85 (0.64 - 1.13)   0.2665 
BRCA1 rs1060915 TAC  0.6500 0.6359 Reference  
 rs1799966 CGT 0.3258 0.3447 1.08 (0.91 - 1.29)   0.3657 
 rs799917      
BRCA2 rs144848 TAA 0.4131 0.4150 Reference  
 rs1799955 GAA 0.2768 0.2953 1.06 (0.87-1.29) 0.5805 
 rs1801406 TGG 0.2241 0.2202 0.97 (0.78-1.20) 0.7520 
  TAG 0.0846 0.0686 0.80 (0.58-1.11) 0.1778 
ERCC1 rs3212948 CCG  0.6040 0.6079 Reference  
 rs3212961 GCT 0.2514 0.2499 0.99 (0.82 - 1.19)   0.9191 
 rs3212986 GAG 0.0940 0.1006 1.08 (0.82 - 1.42)   0.6033 
ERCC2 rs13181 TAGT  0.4639 0.4506 Reference  
 rs1618536 GGAG 0.2649 0.2698 1.04 (0.86 - 1.26)   0.6610 
 rs1799793 TGGG 0.1573 0.1369 0.91 (0.72 - 1.15)   0.4394 
 rs238406      
ERCC3 rs4150416 TGT 0.3970   0.4147 Reference  
 rs4150441 TAT 0.2784 0.2959 1.02 (0.84 - 1.25)   0.8399 
 rs4150474 GAG 0.2587 0.2322 0.86 (0.70 - 1.05)   0.1417 
  GAT 0.0658 0.0572 0.83 (0.58 - 1.18)   0.2973 
ERCC6 rs3793784 CA 0.5372 0.5623 Reference  
 rs4253160 GT 0.4258 0.4049 0.91 (0.77 - 1.07)   0.2543 
EXO1 rs1047840 GGCC  0.2735  0.2780 Reference  
 rs1776148 GATC 0.1460 0.1418 0.92 (0.69 - 1.24)   0.5839 
 rs735943 AATC 0.1454 0.1416 0.93 (0.70 - 1.24)   0.6165 
 rs9350 AGTC 0.0952 0.0749 0.79 (0.55 - 1.14)   0.2077 
  GGTC 0.0671 0.0873 1.18 (0.79 - 1.76)   0.4165 
  AGCT 0.0722 0.0660 0.90 (0.62 - 1.30)   0.5658 
  GGCT 0.0585 0.0550 0.95 (0.63 - 1.45)   0.8211 
LIG4 rs1805386 TC  0.6982 0.6891 Reference  
 rs1805388 CC 0.1692 0.1649 0.98 (0.79 - 1.23)   0.8816 
  TT 0.1326 0.1459 1.12 (0.87 - 1.42)   0.3780 
MLH1 rs1540354 TGGTGG  0.3350  0.3281 Reference  
 rs1799977 TAACAA 0.2410 0.2429 1.03 (0.83 - 1.28)   0.7602 
 rs1800734 TAGCAA 0.1476 0.1505 1.05 (0.82 - 1.34)   0.7130 
 rs2286940 TAGTGG 0.1396 0.1403 1.03 (0.80 - 1.33)   0.8309 
 rs4234259 AAGCAA 0.1215 0.1085 0.93 (0.71 - 1.21)   0.5832 
 rs9876116      
MRE11A rs569143 CG  0.4895 0.5232 Reference  
 rs601341 GA 0.4438 0.4108 0.86 (0.73 - 1.02)   0.0873 
  GG 0.06520 0.06490 0.95 (0.68 - 1.32)   0.7410 
MSH2 rs1981928 TT 0.7227 0.7276 Reference  
 rs2303428 AT 0.1810 0.1627 0.90 (0.72 - 1.12)   0.3330 
  AC 0.0943 0.1096 1.14 (0.87 - 1.49)   0.3343 
MSH3 rs10079641 CCAG 0.3845 0.4021 Reference  
 rs1650697 CCGG 0.1773 0.1823 0.98 (0.76 - 1.25) 0.8473 
 rs26279 CTGA 0.1341 0.1330 0.94 (0.73 - 1.22)   0.6430 
 rs26779 CTAA 0.1134 0.0907 0.76 (0.55 - 1.05)   0.1004 
  GCAA 0.0975 0.0903 0.89 (0.66 - 1.20)   0.4304 
  CCAA 0.0603 0.0560 0.87 (0.59 - 1.28)   0.4744 
MSH6 rs1800935 TATT 0.4574 0.4839 Reference  
 rs2020911 CTTG 0.1597 0.1954 1.15 (0.92 - 1.43)   0.2267 
 rs2348244 TTCT   0.1356 0.1132 0.79 (0.61 - 1.03)   0.0762 
 rs3136228 CATG 0.1132 0.1046 0.89 (0.66 - 1.18)   0.4166 
  TATG   0.0701 0.0606 0.84 (0.60 - 1.18)   0.3051 
OGG1 rs1052133 CT 0.6140 0.6230 Reference  
 rs293794 GT 0.2137 0.2023 0.93 (0.76 - 1.15)   0.5062 
  CC 0.1687 0.1705 0.99 (0.79 - 1.25)   0.9558 
PMS2 rs2228006 GAG 0.4481 0.4521 Reference  
 rs2345060 GGG 0.2496 0.2227 0.89 (0.72 - 1.09)   0.2671 
 rs7797466 AAG 0.1508 0.1623 1.06 (0.83 - 1.35)   0.6342 
  GAA 0.1475 0.1629 1.09 (0.86 - 1.38)   0.4831 
RAD52 rs11226 CT 0.5969 0.5477 Reference  
 rs6413436 TC 0.3225 0.3533 1.19 (1.00 - 1.41)   0.0494 
  TT 0.0778 0.0959 1.34 (0.99 - 1.81)   0.0594 
WRN rs1346044 TT 0.6382 0.6738 Reference  
 rs1800389 CC 0.1345 0.1232 0.87 (0.68 - 1.12)   0.2796 
  TC 0.1331 0.1204 0.87 (0.67 - 1.12)   0.2713 
  CT 0.0942 0.0826 0.83 (0.61 - 1.14)   0.2533 
XPC rs2228000 CC 0.3958 0.3923 Reference  
 rs2228001 TA 0.3275 0.2844 0.87 (0.72 - 1.06)   0.1658 
  CA 0.2767 0.323 1.18 (0.97 - 1.45)   0.0965 
XRCC1 rs25487 GC 0.3756 0.3842 Reference  
 rs3213245 AT 0.3655 0.3442 0.88 (0.74 - 1.06)   0.1685 
  GT 0.2406 0.2526 1.00 (0.81 - 1.24)   0.9756 
XRCC2 rs2040639 AG 0.4649 0.4347 Reference  
 rs3218536 GG 0.4363 0.4616 1.13 (0.95 - 1.33)   0.1605 
  GA 0.0988 0.1036 1.13 (0.85 - 1.50)   0.4128 
XRCC3 rs1799794 GAGGC 0.2575 0.2444 Reference  
 rs1799796 AAATT 0.2273 0.2469 1.15 (0.91 - 1.45)   0.2452 
 rs861528 AGGGC 0.2428 0.2237 0.96 (0.76 - 1.21)   0.7108 
 rs861531 AAGTT 0.1466 0.1320    0.94 (0.72 - 1.24)   0.6761 
 rs861539 AAGGC 0.1173 0.1316 1.16 (0.88 - 1.52)   0.2948 
XRCC4 rs13180316 GTTA 0.3073 0.31894 Reference  
 rs1478485 ACGA 0.2521 0.22915 0.90 (0.72 - 1.12)   0.3596 
 rs2075685 GCGA 0.1730 0.1677 0.95 (0.73 - 1.23)   0.7048 
 rs963248 GCGG 0.1111 0.12020 1.00 (0.75 - 1.34)   0.9823 
XRCC5 rs1051677 TAGT 0.4413    0.4477 Reference  
 rs1051685 TAGC 0.3271 0.3142 0.94 (0.78 - 1.14)   0.5551 
 rs207906 CAGC 0.0882 0.0970 1.09 (0.81 - 1.46)   0.5885 
 rs2440 TGAC 0.0797   0.0771 0.95 (0.70 - 1.30)   0.7626 
GC, gastric cancer; OR, odds ratio; CI, confidence interval.  
Haplotypes with frequencies > 0.05 are shown in the table. 
Odds ratios and 95% confidence intervals were calculated taking as a reference the more common 
haplotype.  
 
Supplementary Table 12: Characteristics of candidate SNPs analyzed in the study. 
SNPa Pathwayb Gene Chr Positionc SNP Type Allelesd MAF HWEe Total N (%) 
rs3219489 MMR MUTYH 1 45331833 Q324H G/C 0.27 0.542 1192 (98.8) 
rs3219484 MMR MUTYH 1 45334484 V22M G/A NA NA ― 
rs1048771 HR RAD54L 1 46278228 A730A C/T 0.12 0.412 1126 (93.4) 
rs1136410 BER PARP1 1 226367601 V762A T/C 0.13 0.263 1206 (100) 
rs735943 MMR EXO1 1 241866849 H354R C/T 0.47 0.086 1201 (99.6) 
rs1047840 MMR EXO1 1 241878999 E589K G/A 0.39 0.932 1190 (98.7) 
rs1776148 MMR EXO1 1 241879243 E670G G/A 0.39 0.863 1200 (99.5) 
rs9350 MMR EXO1 1 241885372 P757L C/T 0.15 0.215 1195 (99.1) 
rs1863332 MMR MSH2 2 47402759 Upstream  A/C 0.08 0.032 1027 (85.2) 
rs2303426 MMR MSH2 2 47403411 Intronic G/C NA NA ― 
rs1981928 MMR MSH2 2 47445336 Intronic T/A 0.27 1.000 1200 (99.5) 
rs2303428 MMR MSH2 2 47476361 Intronic T/C 0.10 0.153 1204 (99.8) 
rs3136228 MMR MSH6 2 47782677 Upstream T/G 0.35 0.717 1197 (99.3) 
rs2348244 MMR MSH6 2 47792346 Intronic T/C 0.13 1.000 1205 (99.9) 
rs1800935 MMR MSH6 2 47795976 D180D T/C 0.29 0.682 1197 (99.3) 
rs2020911 MMR MSH6 2 47803699 Intronic A/T 0.35 0.533 1204 (99.8) 
rs4150474 NER ERCC3 2 127275751 Intronic T/G 0.24 0.199 1203 (99.8) 
rs4150441 NER ERCC3 2 127283339 Intronic A/G 0.41 0.733 1199 (99.4) 
rs4150416 NER ERCC3 2 127288972 Intronic T/G 0.31 0.457 1204 (99.8) 
rs207906 NHEJ XRCC5 2 216148178 T524T G/A 0.12 0.351 1205 (99.9) 
rs1051677 NHEJ XRCC5 2 216205525 3´ UTR T/C 0.09 1.000 1204 (99.8) 
rs1051685 NHEJ XRCC5 2 216205653 3´ UTR A/G 0.10 0.062 1204 (99.8) 
rs2440 NHEJ XRCC5 2 216206043 3´ UTR C/T 0.45 0.804 1203 (99.8) 
rs1052133 BER OGG1 3 9757089 S326C C/G 0.21 0.632 1206 (100) 
rs293794 BER OGG1 3 9761943 Intronic T/C 0.17 0.670 1198 (99.3) 
rs2228001 NER XPC 3 14145949 K939Q A/C 0.39 0.865 1128 (93.5) 
rs2228000 NER XPC 3 14158387 A499V C/T 0.31 0.403 1198 (99.3) 
rs1800734 MMR MLH1 3 36993455 5´ UTR G/A 0.24 0.267 1195 (99.1) 
rs1540354 MMR MLH1 3 37002998 Intronic T/A 0.12 0.124 1202 (99.7) 
rs4234259 MMR MLH1 3 37007142 Intronic A/G 0.49 0.101 1197 (99.3) 
rs1799977 MMR MLH1 3 37012077 I219V A/G 0.33 0.360 1206 (100) 
rs2286940 MMR MLH1 3 37028615 Intronic C/T 0.49 0.120 1200 (99.5) 
rs9876116 MMR MLH1 3 37042249 Intronic A/G 0.48 0.087 1201 (99.6) 
rs1802904 CCC ATR 3 142449489 Q2625Q A/G 0.13 0.264 1202 (99.7) 
rs2227928 CCC ATR 3 142562770 M211T C/T NA NA ― 
rs1650697 MMR MSH3 5 80654962 V79T C/T 0.25 0.458 1116 (92.5) 
rs26779 MMR MSH3 5 80763384 Intronic G/A 0.39 0.398 1201 (99.6) 
rs10079641 MMR MSH3 5 80798145 Intronic C/G 0.10 0.381 1182 (98.0) 
rs184967 MMR MSH3 5 80854162 Q949R G/A NA NA ― 
rs26279 MMR MSH3 5 80873118 A1045T A/G 0.32 0.110 1203 (99.8) 
rs2075685 NHEJ XRCC4 5 83076846 Upstream G/T 0.44 1.000 1204 (99.8) 
rs1478485 NHEJ XRCC4 5 83084708 Intronic C/T 0.41 0.865 1203 (99.8) 
rs13180316 NHEJ XRCC4 5 83163634 Intronic G/A 0.27 1.000 1194 (99.0) 
rs963248 NHEJ XRCC4 5 83238075 Intronic A/G 0.16 1.000 1205 (99.9) 
rs2252775 NHEJ RAD50 5 132582752 Intronic A/C 0.21 0.062 1202 (99.7) 
rs2228006 MMR PMS2 7 5987144 K541E G/A 0.16 0.053 1126 (93.4) 
rs2345060 MMR PMS2 7 5999498 Intronic A/G 0.24 1.000 1203 (99.8) 
rs7797466 MMR PMS2 7 6007152 Intronic G/A 0.16 0.056 1203 (99.8) 
rs3218536 HR XRCC2 7 152648922 R188H G/A 0.10 0.253 1205 (99.9) 
rs2040639 HR XRCC2 7 152678103 Upstream G/A 0.45 0.566 1194 (99.0) 
rs1800389 NHEJ WRN 8 31067041 C171C T/C 0.26 0.214 1199 (99.4) 
rs1346044 NHEJ WRN 8 31167138 C1367R T/C 0.22 0.563 1199 (99.4) 
rs12678588 BER POLB 8 42355555 Q137R G 0.00 NA 1206 (100) 
rs2272615 BER POLB 8 42361530 Downstream A/G 0.12 0.449 1190 (98.7) 
rs1805794 NHEJ NBS1 8 89978251 E185Q C/G 0.30 0.138 1204 (99.8) 
rs1800975 NER XPA 9 97697296 5´ UTR G/A 0.31 0.637 1197 (99.3) 
rs2228526 NER ERCC6 10 49470671 M1097V A/G NA NA ― 
rs4253160 NER ERCC6 10 49485920 Intronic A/T 0.45 0.461 1201 (99.6) 
rs2228524 NER ERCC6 10 49532830 L45L G/C 0.26 0.437 1066 (88.4) 
rs3793784 NER ERCC6 10 49539493 5´ UTR C/G 0.42 0.319 1199 (99.4) 
rs12917 DR MGMT 10 129708019 L84F C/T 0.14 0.865 1065 (88.3) 
rs2308321 DR MGMT 10 129766800 I174V A/G 0.09 0.014 1144 (94.9) 
rs2434470 DR ALKBH3 11 43919052 E228D C/G 0.23 0.911 1198 (99.3) 
rs174538 BER FEN1 11 61792609 Upstream G/A 0.30 0.558 1112 (92.2) 
rs601341 HR MRE11A 11 94434611 Intronic G/A 0.43 0.408 1198 (99.3) 
rs569143 HR MRE11A 11 94455221 Intronic C/G 0.49 0.807 1199 (99.4) 
rs4987876 CCC ATM 11 108221910 Intronic G/T 0.09 0.085 1201 (99.6) 
rs1801516 CCC ATM 11 108304735 D1853N G/A 0.14 0.602 1204 (99.8) 
rs664143 CCC ATM 11 108354934 Intronic C/T 0.37 0.932 1204 (99.8) 
rs11226 HR RAD52 12 912647 3´ UTR C/T 0.43 0.864 1118 (92.7) 
rs6413436 HR RAD52 12 913513 Intronic T/C 0.34 0.926 1203 (99.8) 
rs1059262 DR ALKBH2 12 109087930 3´ UTR T/G 0.18 0.789 1203 (99.8) 
rs5744934 NER POLE 12 132643940 S1396N A/G 0.17 1.000 1200 (99.5) 
rs5744751 NER POLE 12 132677409 A252V C/T NA NA ― 
rs144848 HR BRCA2 13 32332592 N372H T/G 0.29 0.154 1201 (99.6) 
rs1801406 HR BRCA2 13 32337751 K1132K A/G 0.30 0.634 1202 (99.7) 
rs1799955 HR BRCA2 13 32355095 S2414S A/G 0.22 0.484 1205 (99.9) 
rs1047768 NER ERCC5 13 102852167 H46H C/T 0.42 0.452 1204 (99.8) 
rs17655 NER ERCC5 13 102875652 D1104H C/G 0.26 0.540 1201 (99.6) 
rs1805386 NHEJ LIG4 13 108209565 D568D T/C 0.17 0.662 1200 (99.5) 
rs1805388 NHEJ LIG4 13 108211243 T9I C/T 0.14 1.000 1113 (92.3) 
rs1760944 BER APEX1 14 20454990 Upstream C/A 0.38 0.364 1090 (90.4) 
rs1130409 BER APEX1 14 20456995 D148E T/G 0.48 1.000 1201 (99.6) 
rs10483813 HR RAD51B 14 68564567 Intronic T/A NA NA ― 
rs175080 MMR MLH3 14 75047125 L844P G/A 0.44 0.280 1194 (99.0) 
rs861539 HR XRCC3 14 103699416 T241M C/T 0.37 0.603 1206 (100) 
rs1799796 HR XRCC3 14 103699590 Intronic A/G 0.23 0.375 1202 (99.7) 
rs861531 HR XRCC3 14 103706470 Intronic G/T 0.39 0.794 1192 (98.8) 
rs1799794 HR XRCC3 14 103712930 5´ UTR A/G 0.25 0.669 1201 (99.6) 
rs861528 HR XRCC3 14 103716661 Intronic G/A 0.25 0.727 1116 (92.5) 
rs7182283 BER NEIL1 15 75351418 Intronic G/T 0.47 0.163 1191 (98.8) 
rs176641 BER POLG 15 89346951 Upstream A/C 0.36 0.589 1205 (99.9) 
rs3136038 NER ERCC4 16 13919522 Upstream C/T 0.36 0.262 1202 (99.7) 
rs2238463 NER ERCC4 16 13924045 Intronic C/G 0.38 0.269 1203 (99.8) 
rs1800067 NER ERCC4 16 13935176 R415Q G/A 0.12 0.698 1189 (98.6) 
rs1799801 NER ERCC4 16 13948101 S835S T/C 0.30 0.925 1202 (99.7) 
rs9894946 CCC TP53 17 7667762 Intronic G/A 0.15 0.771 1188 (98.5) 
rs1614984 CCC TP53 17 7668134 Downstream C/T 0.40 0.727 1113 (92.3) 
rs1042522 CCC TP53 17 7676154 P72R G/C 0.25 0.41 1204 (99.8) 
rs2074522 BER LIG3 17 35002629 Intronic G/A 0.08 0.565 1203 (99.8) 
rs1799966 HR BRCA1 17 43071077 S1613G A/G 0.34 0.784 1198 (99.3) 
rs3737559 HR BRCA1 17 43082287 Intronic G/A 0.07 1.000 988 (81.9) 
rs1060915 HR BRCA1 17 43082453 S1436S T/C 0.34 0.781 1203 (99.8) 
rs799917 HR BRCA1 17 43092919 P871L C/T 0.36 0.529 1200 (99.5) 
rs4986764 HR BRIP1 17 61685986 S919P C/T 0.38 0.107 1199 (99.4) 
rs4968451 HR BRIP1 17 61849946 Intronic A/C 0.17 0.778 1201 (99.6) 
rs2048718 HR BRIP1 17 61863458 Upstream C/T 0.42 1.000 1159 (96.1) 
rs3730668 BER POLI 18 54269477 Upstream G/T 0.42 0.080 1192 (98.8) 
rs8305 BER POLI 18 54294435 A731T A/G 0.27 0.672 1206 (100) 
rs25487 BER XRCC1 19 43551574 Q399R G/A 0.37 0.147 1206 (100) 
rs25489 BER XRCC1 19 43552260 R280H G/A NA NA ― 
rs3213245 BER XRCC1 19 43575535 5´ UTR T/C 0.39 0.795 1203 (99.8) 
rs13181 NER ERCC2 19 45351661 K751Q T/G 0.34 0.200 1205 (99.9) 
rs1799793 NER ERCC2 19 45364001 D312N G/A 0.32 0.445 1205 (99.9) 
rs238406 NER ERCC2 19 45365051 R156R G/T 0.50 0.121 1206 (100) 
rs1618536 NER ERCC2 19 45368348 Intronic G/A 0.48 0.031 1105 (91.6) 
rs3212986 NER ERCC1 19 45409478 Q504K G/T 0.26 0.524 1126 (93.4) 
rs3212961 NER ERCC1 19 45419065 Intronic C/A 0.12 0.550 1205 (99.9) 
rs11615 NER ERCC1 19 45420395 N118N T/C NA NA ― 
rs3212948 NER ERCC1 19 45421104 Intron 3 C/G 0.37 0.136 1197 (99.3) 
rs20580 BER LIG1 19 48151296 A170A C/A 0.49 0.287 1200 (99.5) 
rs3626 BER PCNA 20 5115125 3´ UTR G/C 0.13 0.593 1205 (99.9) 
rs132788 NHEJ XRCC6 22 41663764 G593G G/T NA NA ― 
Chr, chromosome; MAF, minor allele frequency; N, number of individuals successfully genotyped.  
NA, not applied. 
aSNP identification according to the NCBI data base.  
bDNA repair pathway. BER: base excision repair; NER: nucleotide excision repair; MMR: mismatch 
repair; HR: repair of DNA double-strand breaks by homologous recombination; NHEJ: repair of DNA 
double-strand breaks by non homologous end joining; DR: direct repair; CCC: cell cycle checkpoint 
signalling pathway.  
cChromosome position according to the Genome Reference Consortium Human Build 38.p2 
(GRCh38.p2).  
dMajor/minor alleles.  
eHardy–Weinberg equilibrium P values in control population. 
